2,987 results on '"Santini D."'
Search Results
52. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
- Author
-
Iacovelli, R., primary, Ciccarese, C., additional, Brunelli, M., additional, Battelli, N., additional, Buttigliero, C., additional, Caserta, C., additional, Buti, S., additional, Santini, D., additional, Carella, C., additional, Galli, L., additional, Verri, E., additional, Ermacora, P., additional, Merler, S., additional, Masini, C., additional, De Vivo, R., additional, Milesi, L., additional, Spina, F., additional, Rizzo, M., additional, Sperduti, I., additional, Fornarini, G., additional, and Tortora, G., additional
- Published
- 2022
- Full Text
- View/download PDF
53. Gait analysis driven design and 3D printing of plantar foot orthosis
- Author
-
Guiotto, A., primary, Santini, D., additional, Bertoncello, E., additional, and Sawacha, Z., additional
- Published
- 2022
- Full Text
- View/download PDF
54. 1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)
- Author
-
Stellato, M., primary, Buti, S., additional, Maruzzo, M., additional, Bersanelli, M., additional, Ermacora, P., additional, Maiorano, B.A., additional, Prati, V., additional, De Giorgi, U.F.F., additional, Pierantoni, F., additional, Malgeri, A., additional, Mennitto, A., additional, Cavo, A., additional, Vitale, M.G., additional, Santoni, M., additional, Carella, C., additional, Procopio, G., additional, Verzoni, E., additional, and Santini, D., additional
- Published
- 2022
- Full Text
- View/download PDF
55. 413P Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT) + bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies
- Author
-
Fanotto, V., primary, Boccaccino, A., additional, Casagrande, M., additional, Bergamo, F., additional, Spagnoletti, A., additional, Santini, D., additional, Antoniotti, C., additional, Allegrini, G., additional, Daniel, F., additional, Nasca, V., additional, Rossini, D., additional, Zaniboni, A., additional, Borelli, B., additional, Carullo, M., additional, Conca, V., additional, Passardi, A., additional, Tamburini, E., additional, Masi, G., additional, Cremolini, C., additional, and Pella, N., additional
- Published
- 2022
- Full Text
- View/download PDF
56. Development of a methodology for the design and 3D printing of plantar foot orthosis from gait analysis data
- Author
-
Sawacha, Z., primary, Guiotto, A., additional, Santini, D., additional, and Bertoncello, E., additional
- Published
- 2022
- Full Text
- View/download PDF
57. 341P Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study
- Author
-
Conca, V., primary, Germani, M.M., additional, Moretto, R., additional, Giordano, M., additional, Bergamo, F., additional, Prisciandaro, M., additional, Antoniotti, C., additional, Ugolini, C., additional, Santini, D., additional, Cupini, S., additional, Boccaccino, A., additional, Barsotti, G., additional, Pagani, F., additional, Niccoli, C., additional, Zaniboni, A., additional, Passardi, A., additional, Tamburini, E., additional, Latiano, T.P., additional, Fontanini, G., additional, and Cremolini, C., additional
- Published
- 2022
- Full Text
- View/download PDF
58. Pain related to cancer treatments and diagnostic procedures: a no man's land?
- Author
-
Ripamonti, C.I., Bossi, P., Santini, D., and Fallon, M.
- Published
- 2014
- Full Text
- View/download PDF
59. 1827P Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
- Author
-
Cursano, M.C., Valsecchi, A.A., Pantano, F., Di Maio, M., Procopio, G., Berruti, A., Bertoldo, F., Tucci, M., De Giorgi, U., and Santini, D.
- Published
- 2024
- Full Text
- View/download PDF
60. 1716P Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
- Author
-
Catalano, M., Roviello, G., Buti, S., Massari, F., Li, H., Park, S.H., Grande, E., Kucharz, J., Fiala, O., Poprach, A., Buchler, T., Seront, E., Ansari, J., Myint, Z.W., Bhuva, D.M., Bamias, A., Ghosn, M., Andrey, S., Santoni, M., and Santini, D.
- Published
- 2024
- Full Text
- View/download PDF
61. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
- Author
-
Cortellini, A, Di Maio, M, Nigro, O, Leonetti, A, Cortinovis, D, Aerts, J, Guaitoli, G, Barbieri, F, Giusti, R, Ferrara, M, Bria, E, D'Argento, E, Grossi, F, Rijavec, E, Guida, A, Berardi, R, Torniai, M, Sforza, V, Genova, C, Mazzoni, F, Garassino, M, De Toma, A, Signorelli, D, Gelibter, A, Siringo, M, Marchetti, P, Macerelli, M, Rastelli, F, Chiari, R, Rocco, D, Della Gravara, L, Inno, A, Michele, T, Grassadonia, A, Di Marino, P, Mansueto, G, Zoratto, F, Filetti, M, Santini, D, Citarella, F, Russano, M, Cantini, L, Tuzi, A, Bordi, P, Minuti, G, Landi, L, Ricciardi, S, Migliorino, M, Passiglia, F, Bironzo, P, Metro, G, Adamo, V, Russo, A, Spinelli, G, Banna, G, Friedlaender, A, Addeo, A, Cannita, K, Ficorella, C, Porzio, G, Pinato, D, Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis D, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, Pinato DJ, Cortellini, A, Di Maio, M, Nigro, O, Leonetti, A, Cortinovis, D, Aerts, J, Guaitoli, G, Barbieri, F, Giusti, R, Ferrara, M, Bria, E, D'Argento, E, Grossi, F, Rijavec, E, Guida, A, Berardi, R, Torniai, M, Sforza, V, Genova, C, Mazzoni, F, Garassino, M, De Toma, A, Signorelli, D, Gelibter, A, Siringo, M, Marchetti, P, Macerelli, M, Rastelli, F, Chiari, R, Rocco, D, Della Gravara, L, Inno, A, Michele, T, Grassadonia, A, Di Marino, P, Mansueto, G, Zoratto, F, Filetti, M, Santini, D, Citarella, F, Russano, M, Cantini, L, Tuzi, A, Bordi, P, Minuti, G, Landi, L, Ricciardi, S, Migliorino, M, Passiglia, F, Bironzo, P, Metro, G, Adamo, V, Russo, A, Spinelli, G, Banna, G, Friedlaender, A, Addeo, A, Cannita, K, Ficorella, C, Porzio, G, Pinato, D, Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis D, Aerts JG, Guaitoli G, Barbieri F, Giusti R, Ferrara MG, Bria E, D'Argento E, Grossi F, Rijavec E, Guida A, Berardi R, Torniai M, Sforza V, Genova C, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Della Gravara L, Inno A, Michele T, Grassadonia A, Di Marino P, Mansueto G, Zoratto F, Filetti M, Santini D, Citarella F, Russano M, Cantini L, Tuzi A, Bordi P, Minuti G, Landi L, Ricciardi S, Migliorino MR, Passiglia F, Bironzo P, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Cannita K, Ficorella C, Porzio G, and Pinato DJ
- Abstract
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients with non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative is matter of debate. Methods We present the outcomes analysis according to concomitant baseline medications (prior to ICI initiation) with putative immune-modulatory effects in a large cohort of patients with metastatic NSCLC with a PD-L1 expression >= 50%, receiving first-line pembrolizumab monotherapy. We also evaluated a control cohort of patients with metastatic NSCLC treated with first-line chemotherapy. The interaction between key medications and therapeutic modality (pembrolizumab vs chemotherapy) was validated in pooled multivariable analyses. Results 950 and 595 patients were included in the pembrolizumab and chemotherapy cohorts, respectively. Corticosteroid and proton pump inhibitor (PPI) therapy but not ATB therapy was associated with poorer performance status at baseline in both the cohorts. No association with clinical outcomes was found according to baseline statin, aspirin, beta-blocker and metformin within the pembrolizumab cohort. On the multivariable analysis, ATB emerged as a strong predictor of worse overall survival (OS) (HR=1.42 (95% CI 1.13 to 1.79); p=0.0024), and progression free survival (PFS) (HR=1.29 (95% CI 1.04 to 1.59); p=0.0192) in the pembrolizumab but not in the chemotherapy cohort. Corticosteroids were associated with shorter PFS (HR=1.69 (95% CI 1.42 to 2.03); p<0.0001), and OS (HR=1.93 (95% CI 1.59 to 2.35); p<0.0001) following pembrolizumab, and shorter PFS (HR=1.30 (95% CI 1.08 to 1.56), p=0.0046) and OS (HR=1.58 (95% CI 1.29 to 1.94), p<0.0001), following chemotherapy. PPIs were associated with worse OS (HR=1.49 (95% CI 1.26 to 1.77); p<0.0001) with pem
- Published
- 2021
62. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
- Author
-
Cazzaniga, M, Vallini, I, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Baldelli, A, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Sarti, S, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Di Mauro, P, Cogliati, V, Capici, S, Clivio, L, Torri, V, Cazzaniga M. E., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Baldelli A., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Marchetti P., Sarti S., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Saracchini S., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Di Mauro P., Cogliati V., Capici S., Clivio L., Torri V., Cazzaniga, M, Vallini, I, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Baldelli, A, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Sarti, S, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Di Mauro, P, Cogliati, V, Capici, S, Clivio, L, Torri, V, Cazzaniga M. E., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Baldelli A., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Marchetti P., Sarti S., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Saracchini S., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Di Mauro P., Cogliati V., Capici S., Clivio L., and Torri V.
- Abstract
Purpose: Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting. Methods: We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrospective cohort study, which collected data of metastatic breast cancer (MBC) patients who have received mCHT between 2011 and 2016. Amongst the 584 patients included in the study, 97 were triple negative. In 40.2% of the TNBC patients, mCHT was the first chemotherapy treatment, whereas 32.9% had received 2 or more lines of treatment for the metastatic disease. 45.4% out of 97 TNBC patients received a vinorelbine (VRL)-based regimen, which resulted in the most used type of mCHT, followed by cyclophosphamide (CTX)-based regimens (30.9%) and capecitabine (CAPE)-based combinations (22.7%). Results: Overall response rate (ORR) and disease control rate (DCR) were 17.5% and 64.9%, respectively. Median progression free survival (PFS) and overall survival (OS) were 6.0 months (95% CI: 4.9–7.2) and 12.1 months (95% CI: 9.6–16.7). Median PFS was 6.9 months for CAPE-based regimens (95% CI: 5.0–18.4), 6.1 months (95% CI: 4.0–8.9) for CTX-based and 5.3 months (95% CI: 4.1–9.5) for VRL-based ones. Median OS was 18.2 months (95% CI: 9.1-NE) for CAPE-based regimens and 11.8 months for VRL- (95% CI: 9.3–16.7 and CTX-based ones (95%CI: 8.7–52.8). Tumour response, PFS and OS decreased proportionally in later lines. Conclusion: This analysis represents the largest series of TNBC patients treated with mCHT in
- Published
- 2021
63. Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
- Author
-
Cereda, S., Milella, M., Cordio, S., Leone, F., Aprile, G., Galiano, A., Mosconi, S., Vasile, E., Santini, D., Belli, C., Auriemma, A., Novarino, A., Vaccaro, V., Martines, C., Marino, D., Lutrino, S. E., Palazzo, V., Reinach, B., Aldrighetti, L., and Reni, M.
- Published
- 2016
- Full Text
- View/download PDF
64. O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials
- Author
-
Martinelli, E., primary, Martini, G., additional, Ciardiello, D., additional, Famiglietti, V., additional, Rossini, D., additional, Antoniotti, C., additional, Troiani, T., additional, Napolitano, S., additional, Esposito, L., additional, Latiano, T., additional, Maiello, E., additional, Del Re, M., additional, Lonardi, S., additional, Aprile, G., additional, Santini, D., additional, Masi, G., additional, Avallone, A., additional, Normanno, N., additional, Pietrantonio, F., additional, Pinto, C., additional, Ciardiello, F., additional, and Cremolini, C., additional
- Published
- 2022
- Full Text
- View/download PDF
65. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes
- Author
-
Cortellini, A, Leonetti, A, Catino, A, Pizzutillo, P, Ricciuti, B, De Giglio, A, Chiari, R, Bordi, P, Santini, D, Giusti, R, De Tursi, M, Brocco, D, Zoratto, F, Rastelli, F, Citarella, F, Russano, M, Filetti, M, Marchetti, P, Berardi, R, Torniai, M, Cortinovis, D, Sala, E, Maggioni, C, Follador, A, Macerelli, M, Nigro, O, Tuzi, A, Iacono, D, Migliorino, M, Banna, G, Porzio, G, Cannita, K, Ferrara, M, Bria, E, Galetta, D, Ficorella, C, Tiseo, M, Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M., Cortellini, A, Leonetti, A, Catino, A, Pizzutillo, P, Ricciuti, B, De Giglio, A, Chiari, R, Bordi, P, Santini, D, Giusti, R, De Tursi, M, Brocco, D, Zoratto, F, Rastelli, F, Citarella, F, Russano, M, Filetti, M, Marchetti, P, Berardi, R, Torniai, M, Cortinovis, D, Sala, E, Maggioni, C, Follador, A, Macerelli, M, Nigro, O, Tuzi, A, Iacono, D, Migliorino, M, Banna, G, Porzio, G, Cannita, K, Ferrara, M, Bria, E, Galetta, D, Ficorella, C, Tiseo, M, Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, and Tiseo M.
- Abstract
Background: In most cases, T790M EGFR-positive NSCLC patients receiving osimertinib developed “non-drugable” progression, as the patients with common EGFR-sensitizing mutations were treated with first-line osimertinib. In both settings, chemotherapy represents the standard treatment and local ablative treatments (LATs) are potential useful options in the case of oligo-progression. Methods: We conducted a study on “post-progression” (pp) outcomes of T790M EGFR-positive NSCLC patients treated with osimertinib, according to the therapeutic strategy applied: osimertinib beyond progression (± LATs), “switched therapies” or best supportive care only (BSC). Results: 144 consecutive patients were evaluated: 53 (36.8%) did not received post-progression treatments (BSC), while 91 (63.2%) patients received at least 1 subsequent treatment; 50 patients (54.9%) received osimertinib beyond disease progression [19 (20.9%) of them with adjunctive LATs] and 41 (45.1%) a switched therapy. Median ppPFS (progression-free survival) and median ppOS (overall survival) of patients who received osimertinib beyond progression vs. switched therapies were 6.4 months vs. 4.7 months, respectively [HR 0.57 (95% CI 0.35–0.92), p = 0.0239] and 11.3 months vs 7.8 months, respectively [HR 0.57 (95% CI 0.33–0.98), p = 0.0446]. Among patients who received osimertinib beyond progression with and without LATs median ppPFS was 6.4 months and 5.7 months, respectively [HR 0.90 (95% CI 0.68–1.18), p = 0.4560], while median ppOS was 20.2 months and 9.9 months, respectively [HR 0.73 (95% CI 0.52–1.03), p = 0.0748]. At the univariate analysis, the only factor significantly related to the ppPFS was the therapeutic strategy in favor of osimertinib beyond progression (± LATs). Moreover, the only variable which was significantly related to ppOS at the multivariate analysis was osimertinib beyond progression (± LATs). Conclusion: Our study confirmed that in clinical practice, in case of “non-druggable” disease progre
- Published
- 2020
66. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
- Author
-
Cortellini, A, Friedlaender, A, Banna, G, Porzio, G, Bersanelli, M, Cappuzzo, F, Aerts, J, Giusti, R, Bria, E, Cortinovis, D, Grossi, F, Migliorino, M, Galetta, D, Passiglia, F, Berardi, R, Mazzoni, F, Di Noia, V, Signorelli, D, Tuzi, A, Gelibter, A, Marchetti, P, Macerelli, M, Rastelli, F, Chiari, R, Rocco, D, Inno, A, Di Marino, P, Mansueto, G, Zoratto, F, Santoni, M, Tudini, M, Ghidini, M, Filetti, M, Catino, A, Pizzutilo, P, Sala, L, Occhipinti, M, Citarella, F, Marco, R, Torniai, M, Cantini, L, Follador, A, Sforza, V, Nigro, O, Ferrara, M, D'Argento, E, Leonetti, A, Pettoruti, L, Antonuzzo, L, Scodes, S, Landi, L, Guaitoli, G, Baldessari, C, Bertolini, F, Della Gravara, L, Dal Bello, M, Belderbos, R, De Filippis, M, Cecchi, C, Ricciardi, S, Donisi, C, De Toma, A, Proto, C, Addeo, A, Cantale, O, Ricciuti, B, Genova, C, Morabito, A, Santini, D, Ficorella, C, Cannita, K, Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Marco R, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K., Cortellini, A, Friedlaender, A, Banna, G, Porzio, G, Bersanelli, M, Cappuzzo, F, Aerts, J, Giusti, R, Bria, E, Cortinovis, D, Grossi, F, Migliorino, M, Galetta, D, Passiglia, F, Berardi, R, Mazzoni, F, Di Noia, V, Signorelli, D, Tuzi, A, Gelibter, A, Marchetti, P, Macerelli, M, Rastelli, F, Chiari, R, Rocco, D, Inno, A, Di Marino, P, Mansueto, G, Zoratto, F, Santoni, M, Tudini, M, Ghidini, M, Filetti, M, Catino, A, Pizzutilo, P, Sala, L, Occhipinti, M, Citarella, F, Marco, R, Torniai, M, Cantini, L, Follador, A, Sforza, V, Nigro, O, Ferrara, M, D'Argento, E, Leonetti, A, Pettoruti, L, Antonuzzo, L, Scodes, S, Landi, L, Guaitoli, G, Baldessari, C, Bertolini, F, Della Gravara, L, Dal Bello, M, Belderbos, R, De Filippis, M, Cecchi, C, Ricciardi, S, Donisi, C, De Toma, A, Proto, C, Addeo, A, Cantale, O, Ricciuti, B, Genova, C, Morabito, A, Santini, D, Ficorella, C, Cannita, K, Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Marco R, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, and Cannita K.
- Abstract
Background: The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non-small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%. Patients and methods: We previously conducted a multicenter retrospective analysis in patients with treatment-naive metastatic NSCLC and a PD-L1 expression of ≥ 50% receiving first-line pembrolizumab. Here, we report the results of the irAE analysis and the potential correlation between irAEs and clinical outcomes. Results: A total of 1010 patients were included in this analysis; after a 6-week landmark selection, 877 (86.8%) patients were included in the efficacy analysis. Any grade irAEs (P < .0001), grade 3/4 irAEs (P = .0025), leading to discontinuation irAEs (P = .0144), multiple-site and single-site irAEs (P < .0001), cutaneous irAEs (P = .0001), endocrine irAEs (P = .0227), pulmonary irAEs (P = .0479), and rheumatologic irAEs (P = .0018) were significantly related to a higher objective response rate. Any grade irAEs (P < .0001), single-site irAEs (P < .0001), multiple-site irAEs (P = .0005), cutaneous irAEs (P = .0042), endocrine irAEs (P < .0001), gastrointestinal irAEs (P = .0391), and rheumatologic irAEs (P = .0086) were significantly related to progression-free survival. Any grade irAEs (P < .0001), single-site irAEs (P < .0001), multiple-site irAEs (P = .0003), cutaneous irAEs (P = .0002), endocrine irAEs (P = .0001), and rheumatologic irAEs (P = .0214) were significantly related to overall survival. Conclusions: This study confirms the feasibility and the safety of first-line, single-agent pembrolizumab, in a large, real-world cohort of patients with NSCLC with PD-L1 expression ≥ 50%. The occurrence of irAEs may be a surrogate of clinical activity and improved outcomes in this setting.
- Published
- 2020
67. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50
- Author
-
Cortellini, A, Tiseo, M, Banna, G, Cappuzzo, F, Aerts, J, Barbieri, F, Giusti, R, Bria, E, Cortinovis, D, Grossi, F, Migliorino, M, Galetta, D, Passiglia, F, Santini, D, Berardi, R, Morabito, A, Genova, C, Mazzoni, F, Di Noia, V, Signorelli, D, Tuzi, A, Gelibter, A, Marchetti, P, Macerelli, M, Rastelli, F, Chiari, R, Rocco, D, Gori, S, De Tursi, M, Mansueto, G, Zoratto, F, Santoni, M, Tudini, M, Rijavec, E, Filetti, M, Catino, A, Pizzutilo, P, Sala, L, Citarella, F, Marco, R, Torniai, M, Cantini, L, Targato, G, Sforza, V, Nigro, O, Ferrara, M, D'Argento, E, Buti, S, Bordi, P, Antonuzzo, L, Scodes, S, Landi, L, Guaitoli, G, Baldessari, C, Della Gravara, L, Dal Bello, M, Belderbos, R, Bironzo, P, Carnio, S, Ricciardi, S, Grieco, A, De Toma, A, Proto, C, Friedlaender, A, Cantale, O, Ricciuti, B, Addeo, A, Metro, G, Ficorella, C, Porzio, G, Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G., Cortellini, A, Tiseo, M, Banna, G, Cappuzzo, F, Aerts, J, Barbieri, F, Giusti, R, Bria, E, Cortinovis, D, Grossi, F, Migliorino, M, Galetta, D, Passiglia, F, Santini, D, Berardi, R, Morabito, A, Genova, C, Mazzoni, F, Di Noia, V, Signorelli, D, Tuzi, A, Gelibter, A, Marchetti, P, Macerelli, M, Rastelli, F, Chiari, R, Rocco, D, Gori, S, De Tursi, M, Mansueto, G, Zoratto, F, Santoni, M, Tudini, M, Rijavec, E, Filetti, M, Catino, A, Pizzutilo, P, Sala, L, Citarella, F, Marco, R, Torniai, M, Cantini, L, Targato, G, Sforza, V, Nigro, O, Ferrara, M, D'Argento, E, Buti, S, Bordi, P, Antonuzzo, L, Scodes, S, Landi, L, Guaitoli, G, Baldessari, C, Della Gravara, L, Dal Bello, M, Belderbos, R, Bironzo, P, Carnio, S, Ricciardi, S, Grieco, A, De Toma, A, Proto, C, Friedlaender, A, Cantale, O, Ricciuti, B, Addeo, A, Metro, G, Ficorella, C, Porzio, G, Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, and Porzio G.
- Abstract
Background: Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. Methods: We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness in patients with treatment-naïve NSCLC and a PD-L1 expression of ≥ 50%. Results: One thousand and twenty-six consecutive patients were included. The objective response rate (ORR) was 44.5% (95% CI 40.2–49.1), while the median progression free survival (PFS) and overall survival (OS) were 7.9 months (95% CI 6.9–9.5; 599 events) and 17.2 months (95% CI 15.3–22.3; 598 censored patients), respectively. ECOG-PS ≥ 2 (p < 0.0001) and bone metastases (p = 0.0003) were confirmed to be independent predictors of a worse ORR. Former smokers (p = 0.0002), but not current smokers (p = 0.0532) were confirmed to have a significantly prolonged PFS compared to never smokers at multivariate analysis. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and liver metastases (p < 0.0001) were also confirmed to be independent predictors of a worse PFS. Previous palliative RT was significantly related to a shortened OS (p = 0.0104), while previous non-palliative RT was significantly related to a prolonged OS (p = 0.0033). Former smokers (p = 0.0131), but not current smokers (p = 0.3433) were confirmed to have a significantly prolonged OS compared to never smokers. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and liver metastases (p < 0.0001) were also confirmed to be independent predictors of a shortened OS. A PD-L1 expression of ≥ 90%, as assessed by recursive partitioning, was associated with significantly higher ORR (p = 0.0204), and longer and OS (p = 0.0346) at multivariable analysis. Conclusion: Pembrolizumab was effective in a large cohort of NSCLC patients treated outside of clinical trials. Questions regarding the effe
- Published
- 2020
68. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
- Author
-
Bersanelli, M, Buti, S, Giannarelli, D, Leonetti, A, Cortellini, A, Russo, G, Signorelli, D, Toschi, L, Milella, M, Pilotto, S, Bria, E, Proto, C, Marinello, A, Randon, G, Rossi, S, Vita, E, Sartori, G, D'Argento, E, Qako, E, Giaiacopi, E, Ghilardi, L, Bettini, A, Rapacchi, E, Mazzoni, F, Lavacchi, D, Scotti, V, Ciccone, L, De Tursi, M, Di Marino, P, Santini, D, Russano, M, Bordi, P, Di Maio, M, Audisio, M, Filetti, M, Giusti, R, Berardi, R, Fiordoliva, I, Cerea, G, Pizzutilo, E, Bearz, A, De Carlo, E, Cecere, F, Renna, D, Camisa, R, Caruso, G, Ficorella, C, Banna, G, Cortinovis, D, Brighenti, M, Garassino, M, Tiseo, M, Bersanelli M., Buti S., Giannarelli D., Leonetti A., Cortellini A., Russo G. L., Signorelli D., Toschi L., Milella M., Pilotto S., Bria E., Proto C., Marinello A., Randon G., Rossi S., Vita E., Sartori G., D'Argento E., Qako E., Giaiacopi E., Ghilardi L., Bettini A. C., Rapacchi E., Mazzoni F., Lavacchi D., Scotti V., Ciccone L. P., De Tursi M., Di Marino P., Santini D., Russano M., Bordi P., Di Maio M., Audisio M., Filetti M., Giusti R., Berardi R., Fiordoliva I., Cerea G., Pizzutilo E. G., Bearz A., De Carlo E., Cecere F., Renna D., Camisa R., Caruso G., Ficorella C., Banna G. L., Cortinovis D., Brighenti M., Garassino M. C., Tiseo M., Bersanelli, M, Buti, S, Giannarelli, D, Leonetti, A, Cortellini, A, Russo, G, Signorelli, D, Toschi, L, Milella, M, Pilotto, S, Bria, E, Proto, C, Marinello, A, Randon, G, Rossi, S, Vita, E, Sartori, G, D'Argento, E, Qako, E, Giaiacopi, E, Ghilardi, L, Bettini, A, Rapacchi, E, Mazzoni, F, Lavacchi, D, Scotti, V, Ciccone, L, De Tursi, M, Di Marino, P, Santini, D, Russano, M, Bordi, P, Di Maio, M, Audisio, M, Filetti, M, Giusti, R, Berardi, R, Fiordoliva, I, Cerea, G, Pizzutilo, E, Bearz, A, De Carlo, E, Cecere, F, Renna, D, Camisa, R, Caruso, G, Ficorella, C, Banna, G, Cortinovis, D, Brighenti, M, Garassino, M, Tiseo, M, Bersanelli M., Buti S., Giannarelli D., Leonetti A., Cortellini A., Russo G. L., Signorelli D., Toschi L., Milella M., Pilotto S., Bria E., Proto C., Marinello A., Randon G., Rossi S., Vita E., Sartori G., D'Argento E., Qako E., Giaiacopi E., Ghilardi L., Bettini A. C., Rapacchi E., Mazzoni F., Lavacchi D., Scotti V., Ciccone L. P., De Tursi M., Di Marino P., Santini D., Russano M., Bordi P., Di Maio M., Audisio M., Filetti M., Giusti R., Berardi R., Fiordoliva I., Cerea G., Pizzutilo E. G., Bearz A., De Carlo E., Cecere F., Renna D., Camisa R., Caruso G., Ficorella C., Banna G. L., Cortinovis D., Brighenti M., Garassino M. C., and Tiseo M.
- Abstract
Objectives: In the most of cases, for non-small cell lung cancer (NSCLC) patients who progressed to previous immune checkpoint inhibitors (CKI) administered as first- or as second-line therapy, chemotherapy (CT) remains the only viable options in the absence of “druggable” mutations. We aimed to explore the efficacy of salvage chemotherapy after immunotherapy (SCAI) in advanced NSCLC patients. Materials and Methods: We designed a retrospective, multicenter study, involving 20 Italian centers, with the primary objective of describing the clinical outcome of advanced NSCLC patients treated with SCAI at the participating institutions from November 2013 to July 2019. The primary endpoint of the study was represented by overall survival (OS), defined as the time from CT initiation to death. Secondary outcome endpoints of the SCAI (progression free survival, PFS, objective response rate, ORR and toxicity) and explorative biomarkers (lactate dehydrogenase, LDH, and neutrophil-to-lymphocyte ratio, NLR during immunotherapy) were also analyzed. Results: In our study population of 342 NSCLC patients, SCAI obtained a median OS of 6.8 months (95 % confidence interval, CI 5.5–8.1), median PFS of 4.1 months (95 % CI 3.4−4.8) and ORR of 22.8 %. A “Post-CKI score” was constructed by combining significant predictors of OS at the multivariate analyses (sex, ECOG PS, disease control with prior immunotherapy), Harrell'C was 0.65, (95 % CI:0.59−0.71). Conclusions: Despite the late-line settings, our findings support the hypothesis that previous immunotherapy might increase the sensitivity of the tumor to the subsequent chemotherapy. The “Post-CKI score” was clinically effective in successfully discriminating three distinct prognostic subgroups of patients after the failure of CKI, representing a possibly useful tool for the tailored decision-making process of advanced treatment-line settings in NSCLC.
- Published
- 2020
69. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
- Author
-
Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Gianni, L, Michelotti, A, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, De Laurentiis, M, Atzori, F, Turletti, A, Porpiglia, M, Santini, D, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Giordano, M, Donadio, M, Biganzoli, L, Del Mastro, L, Bisagni, G, Livi, L, Natoli, C, Montemurro, F, Riccardi, F, Romagnoli, E, Marchetti, P, Torri, V, Pronzato, P, Mustacchi, G, Cazzaniga M. E., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Gianni L., Michelotti A., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G. V., Artale S., Blasi L., De Laurentiis M., Atzori F., Turletti A., Porpiglia M., Santini D., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Giordano M., Donadio M., Biganzoli L., Del Mastro L., Bisagni G., Livi L., Natoli C., Montemurro F., Riccardi F., Romagnoli E., Marchetti P., Torri V., Pronzato P., Mustacchi G., Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Gianni, L, Michelotti, A, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, De Laurentiis, M, Atzori, F, Turletti, A, Porpiglia, M, Santini, D, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Giordano, M, Donadio, M, Biganzoli, L, Del Mastro, L, Bisagni, G, Livi, L, Natoli, C, Montemurro, F, Riccardi, F, Romagnoli, E, Marchetti, P, Torri, V, Pronzato, P, Mustacchi, G, Cazzaniga M. E., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Gianni L., Michelotti A., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G. V., Artale S., Blasi L., De Laurentiis M., Atzori F., Turletti A., Porpiglia M., Santini D., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Giordano M., Donadio M., Biganzoli L., Del Mastro L., Bisagni G., Livi L., Natoli C., Montemurro F., Riccardi F., Romagnoli E., Marchetti P., Torri V., Pronzato P., and Mustacchi G.
- Abstract
Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.
- Published
- 2020
70. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting
- Author
-
Pizzuti, L, Krasniqi, E, Barchiesi, G, Della Giulia, M, Izzo, F, Sanguineti, G, Marchetti, P, Mazzotta, M, Giusti, R, Botticelli, A, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Iezzi, L, Tomao, S, Tomao, F, Tonini, G, Santini, D, Astone, A, Michelotti, A, De Angelis, C, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Rossi, E, Cazzaniga, M, Moscetti, L, Omarini, C, Piacentini, F, Fabbri, M, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Samaritani, R, Garufi, C, Barni, S, Mirabelli, R, Sarmiento, R, Veltri, E, D'Auria, G, Paris, I, Giotta, F, Lorusso, V, Cardillo, F, Landucci, E, Mauri, M, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Berardi, R, Pistelli, M, Fiorio, E, Cannita, K, Sini, V, D'Ostilio, N, Foglietta, J, Greco, F, Zamagni, C, Garrone, O, Di Cocco, B, Baldini, E, Livi, L, Desideri, I, Meattini, I, Sarobba, G, Del Medico, P, De Tursi, M, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Sperduti, I, Villa, A, Barba, M, Di Leo, A, Vici, P, Pizzuti L., Krasniqi E., Barchiesi G., Della Giulia M., Izzo F., Sanguineti G., Marchetti P., Mazzotta M., Giusti R., Botticelli A., Gamucci T., Natoli C., Grassadonia A., Tinari N., Iezzi L., Tomao S., Tomao F., Tonini G., Santini D., Astone A., Michelotti A., De Angelis C., Mentuccia L., Vaccaro A., Magnolfi E., Gelibter A., Magri V., Cortesi E., D'Onofrio L., Cassano A., Rossi E., Cazzaniga M., Moscetti L., Omarini C., Piacentini F., Fabbri M. A., Scinto A. F., Corsi D., Carbognin L., Bria E., La Verde N., Samaritani R., Garufi C., Barni S., Mirabelli R., Sarmiento R., Veltri E. M., D'Auria G., Paris I., Giotta F., Lorusso V., Cardillo F., Landucci E., Mauri M., Ficorella C., Roselli M., Adamo V., Ricciardi G. R. R., Russo A., Berardi R., Pistelli M., Fiorio E., Cannita K., Sini V., D'Ostilio N., Foglietta J., Greco F., Zamagni C., Garrone O., Di Cocco B., Baldini E., Livi L., Desideri I., Meattini I., Sarobba G., Del Medico P., De Tursi M., Generali D., De Maria R., Risi E., Ciliberto G., Sperduti I., Villa A., Barba M., Di Leo A., Vici P., Pizzuti, L, Krasniqi, E, Barchiesi, G, Della Giulia, M, Izzo, F, Sanguineti, G, Marchetti, P, Mazzotta, M, Giusti, R, Botticelli, A, Gamucci, T, Natoli, C, Grassadonia, A, Tinari, N, Iezzi, L, Tomao, S, Tomao, F, Tonini, G, Santini, D, Astone, A, Michelotti, A, De Angelis, C, Mentuccia, L, Vaccaro, A, Magnolfi, E, Gelibter, A, Magri, V, Cortesi, E, D'Onofrio, L, Cassano, A, Rossi, E, Cazzaniga, M, Moscetti, L, Omarini, C, Piacentini, F, Fabbri, M, Scinto, A, Corsi, D, Carbognin, L, Bria, E, La Verde, N, Samaritani, R, Garufi, C, Barni, S, Mirabelli, R, Sarmiento, R, Veltri, E, D'Auria, G, Paris, I, Giotta, F, Lorusso, V, Cardillo, F, Landucci, E, Mauri, M, Ficorella, C, Roselli, M, Adamo, V, Ricciardi, G, Russo, A, Berardi, R, Pistelli, M, Fiorio, E, Cannita, K, Sini, V, D'Ostilio, N, Foglietta, J, Greco, F, Zamagni, C, Garrone, O, Di Cocco, B, Baldini, E, Livi, L, Desideri, I, Meattini, I, Sarobba, G, Del Medico, P, De Tursi, M, Generali, D, De Maria, R, Risi, E, Ciliberto, G, Sperduti, I, Villa, A, Barba, M, Di Leo, A, Vici, P, Pizzuti L., Krasniqi E., Barchiesi G., Della Giulia M., Izzo F., Sanguineti G., Marchetti P., Mazzotta M., Giusti R., Botticelli A., Gamucci T., Natoli C., Grassadonia A., Tinari N., Iezzi L., Tomao S., Tomao F., Tonini G., Santini D., Astone A., Michelotti A., De Angelis C., Mentuccia L., Vaccaro A., Magnolfi E., Gelibter A., Magri V., Cortesi E., D'Onofrio L., Cassano A., Rossi E., Cazzaniga M., Moscetti L., Omarini C., Piacentini F., Fabbri M. A., Scinto A. F., Corsi D., Carbognin L., Bria E., La Verde N., Samaritani R., Garufi C., Barni S., Mirabelli R., Sarmiento R., Veltri E. M., D'Auria G., Paris I., Giotta F., Lorusso V., Cardillo F., Landucci E., Mauri M., Ficorella C., Roselli M., Adamo V., Ricciardi G. R. R., Russo A., Berardi R., Pistelli M., Fiorio E., Cannita K., Sini V., D'Ostilio N., Foglietta J., Greco F., Zamagni C., Garrone O., Di Cocco B., Baldini E., Livi L., Desideri I., Meattini I., Sarobba G., Del Medico P., De Tursi M., Generali D., De Maria R., Risi E., Ciliberto G., Sperduti I., Villa A., Barba M., Di Leo A., and Vici P.
- Abstract
We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression-free survival at first-line (mPFS1) was 12 months. Pertuzumab as first-line conferred longer mPFS1 compared to other first-line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second-line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T-DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing both hormonal receptors (HRs; p = 0.17), while a trend emerged for tumors with one HR (p = 0.05). Conversely, PFS2 gain was significant in HRs-negative tumors (p = 0.04). Median overall survival (mOS) was 74 months, with no significant differences by IHC subtypes. Survival rates at 2 and 3 years in patients treated with T-DM1 in second-line after pertuzumab were significantly lower compared to pertuzumab-naïve patients (p = 0.01). When analyzed by IHC subtype, the outcome was confirmed if both HRs or no HRs were expressed (p = 0.02 and p = 0.006, respectively). Our results confirm that HRs expression impacts the clinical behavior and novel treatment-related outcomes of HER2-positive tumors when treatment sequences are considered. Moreover, multivariate analysis showed that HRs expression had no effect on PFS and OS. Further studies are warranted to confirm our findings and clarify the interplay between HER2 and estrogen receptor pathways in HER2-positive (mbc) patients
- Published
- 2020
71. Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer—single versus double checkpoint inhibition
- Author
-
Marinelli, D., Sabatini, A., Bengala, E., Ciurluini, F., Picone, V., Santini, D., Pietrantonio, F., Rossini, D., and Cremolini, C.
- Published
- 2024
- Full Text
- View/download PDF
72. Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases
- Author
-
Siringo, M, Larocca, F, Spagnuolo, A, Gentile, G, Anile, M, Diso, D, Santini, D, and Gelibter, A
- Published
- 2024
- Full Text
- View/download PDF
73. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
- Author
-
Santini, D, Vincenzi, B, Addeo, R, Garufi, C, Masi, G, Scartozzi, M, Mancuso, A, Frezza, A M, Venditti, O, Imperatori, M, Schiavon, G, Bronte, G, Cicero, G, Recine, F, Maiello, E, Cascinu, S, Russo, A, Falcone, A, and Tonini, G
- Published
- 2017
- Full Text
- View/download PDF
74. P301 Non-familial small bowel carcinomas in Crohnʼs disease: clinico-pathological, molecular and prognostic features
- Author
-
Di Sabatino, A., Vanoli, A., Furlan, D., Giuffrida, P., Klersy, C., Grillo, F., Fiocca, R., Mescoli, C., Rugge, M., Nesi, G., Fociani, P., Sampietro, G., Ardizzone, S., Luinetti, O., Calabrò, A., Tonelli, F., Volta, U., Santini, D., Caio, G., Elli, L., Ferrero, S., Latella, G., Ciardi, A., Solina, G., Rizzo, A., Ciacci, C., DʼArmiento, F.P., Salemme, M., Villanacci, V., Cannizzaro, R., Canzonieri, V., Reggiani Bonetti, L., Biancone, L., Monteleone, G., Orlandi, A., Santeusanio, G., Macciomei, M.C., DʼIncà, R., Perfetti, V., Sandri, G., Silano, M., Florena, A.M., Giannone, A.G., Papi, C., Coppola, L., Usai, P., Maccioni, A., Astegiano, M., Migliora, P., Manca, R., Martino, M., Trapani, D., Cerutti, R., Alberizzi, P., Riboni, R., Sessa, F., Paulli, M., Solcia, E., and Corazza, G.R.
- Published
- 2017
- Full Text
- View/download PDF
75. Congenital cytomegalovirus infection: patterns of fetal brain damage
- Author
-
Gabrielli, L., Bonasoni, M.P., Santini, D., Piccirilli, G., Chiereghin, A., Petrisli, E., Dolcetti, R., Guerra, B., Piccioli, M., Lanari, M., Landini, M.P., and Lazzarotto, T.
- Published
- 2012
- Full Text
- View/download PDF
76. Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis
- Author
-
Berardi, R., Rinaldi, S., Santini, D., Vincenzi, B., Giampieri, R., Maccaroni, E., Marcucci, F., Francoletti, M., Onofri, A., Lucarelli, A., Pierantoni, C., Tonini, G., and Cascinu, S.
- Published
- 2015
- Full Text
- View/download PDF
77. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
- Author
-
Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., Mancuso, A., Frezza, A.M., Venditti, O., Imperatori, M., Schiavon, G., Bronte, G., Cicero, G., Recine, F., Maiello, E., Cascinu, S., Russo, A., Falcone, A., and Tonini, G.
- Published
- 2012
- Full Text
- View/download PDF
78. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
- Author
-
Iacovelli, Roberto R, Ciccarese, C, Brunelli, M, Battelli, N, Buttigliero, C, Caserta, C, Buti, S, Santini, D, Carella, C, Galli, L, Verri, E, Ermacora, P, Merler, S, Masini, C, De Vivo, R, Milesi, L, Spina, F, Rizzo, M, Sperduti, I, Fornarini, G, and Tortora, G
- Subjects
PD-L1 ,Carcinoma, Transitional Cell ,biomarkers ,Hematology ,Antibodies, Monoclonal, Humanized ,B7-H1 Antigen ,cisplatin ineligible ,Urinary Bladder Neoplasms ,Oncology ,Humans ,bladder cancer ,avelumab ,immunotherapy ,Cisplatin ,Aged - Abstract
Cisplatin-based chemotherapy is the most recommended treatment for metastatic urothelial cancer (mUC). However, about 50% of patients are considered to be cisplatin ineligible. Anti-programmed cell death protein 1/programmed death-ligand 1 (PD-L1) therapies have, nevertheless, increased the options available to clinicians and are especially valuable for treating these patients. This study therefore tested the activity and safety of avelumab as first-line therapy for mUC.Patients with mUC who were ineligible for cisplatin-based chemotherapy were screened centrally for PD-L1 expression and only those with a tumour proportion score ≥ 5% were enrolled in the trial. The primary endpoint was 1-year overall survival (OS), and the secondary endpoints were median OS, median progression-free survival, overall response rate, duration of the response, safety and tolerability. All the survival rates were estimated with the Kaplan-Meier product-limit methodology and compared across groups using the log-rank test.A total of 198 patients were screened, with 71 (35.9%) whose PD-L1 expression was ≥5% enrolled in the study. The median age was 75 years, bladder cancer was the primary tumour in 73.2% of cases and 25.3% had liver metastases. The main reasons for the cisplatin ineligibility were a low rate of creatinine clearance (60 ml/min), present in 70.4% of patients, and an Eastern Cooperative Oncology Group performance status of 2, which affected 31%. The median OS was 10.0 months (95% confidence interval 5.5-14.5 months) and 43% of patients were alive at 1 year. A complete response was achieved in 8.5% of cases, and 15.5% had a partial response. Adverse any-grade and high-grade events occurred in 49.3% and 8.5% of patients, respectively. A grade 3 infusion reaction was the only high-grade treatment-related adverse event. No treatment-related deaths were reported.This ARIES trial confirmed the activity and safety of avelumab for treating mUC, adding a new therapy option to the armamentarium of checkpoint inhibitors already approved for platinum-ineligible, locally advanced/mUC.
- Published
- 2022
79. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients
- Author
-
Vincenzi, B., Galluzzo, S., Santini, D., Rocci, L., Loupakis, F., Correale, P., Addeo, R., Zoccoli, A., Napolitano, A., Graziano, F., Ruzzo, A., Falcone, A., Francini, G., Dicuonzo, G., and Tonini, G.
- Published
- 2011
- Full Text
- View/download PDF
80. First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial
- Author
-
Iacovelli, R., primary, Ciccarese, C., additional, Brunelli, M., additional, Battelli, N., additional, Buttigliero, C., additional, Caserta, C., additional, Buti, S., additional, Santini, D., additional, Naglieri, E., additional, Galli, L., additional, Verri, E., additional, Ermacora, P., additional, Milella, M., additional, Masini, C., additional, Aprile, G., additional, Milesi, L., additional, Spina, F., additional, Rizzo, M., additional, Sperduti, I., additional, Fornarini, G., additional, and Tortora, G., additional
- Published
- 2022
- Full Text
- View/download PDF
81. C8 - Brain metastases and ado-trastuzumab emtansine (TDM-1) treatment in HER2 positive metastatic patients: an Italian multicenter analysis
- Author
-
Fabi, A., Alesini, D., Valle, E., Carbognin, L., Arpino, G., Santini, D., Montemurro, F., Ciccarese, M., Cannita, K., Paris, I., Moscetti, L., De Laurentiis, M., Zambelli, A., La Verde, N., Nisticò, C., Ferretti, G., Gasparro, S., Giannarelli, D., and Cognetti, F.
- Published
- 2017
- Full Text
- View/download PDF
82. B4 - Safety and efficacy of cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)
- Author
-
Michele, P., Ratta, R., Iacovelli, R., Mancini, M., Fornarini, G., Facchini, G., Cartenì, G., Napolitano, M., Del Bene, G., Santini, D., Mariella Sorarù, M., Vitale, M.G., Ricotta, R., Tucci, M., Luzi Fedeli, S., Boe, M.G., Mecozzi, A., Ortega, C., Stemberg, C.N., and Procopio, G.
- Published
- 2017
- Full Text
- View/download PDF
83. B10 - Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with Abiraterone in pre-docetaxel setting
- Author
-
Ratta, R., Verzoni, E., Pantano, F., Grassi, P., De Lisi, D., Prisciandaro, M., Montone, R., Sorrentino, M., de Braud, F., Santini, D., and Procopio, G.
- Published
- 2017
- Full Text
- View/download PDF
84. B3 - Impact of metabolic syndrome on clinical outcome of castration resistant prostate cancer (CRPC) patients treated with abiraterone and enzalutamide
- Author
-
Conteduca, V., Caffo, O., Galli, L., Maugeri, A., Scarpi, E., Maines, F., Chiuri, V.E., Lolli, C., Kinspergher, S., Schepisi, G., Santoni, M., Santini, D., Fratino, L., Burgio, S.L., Salvi, S., Menna, C., and de Giorgi, U.
- Published
- 2017
- Full Text
- View/download PDF
85. Employment from Solar Energy: A Bright but Partly Cloudy Future.
- Author
-
Argonne National Lab., IL., Smeltzer, K. K., and Santini, D. J.
- Abstract
A comparison of quantitative and qualitative employment effects of solar and conventional systems can prove the increased employment postulated as one of the significant secondary benefits of a shift from conventional to solar energy use. Current quantitative employment estimates show solar technology-induced employment to be generally greater than for conventional technologies. Discussing the qualitative employment effects focuses on the relative size and spatial distribution of the various technologies. The effects of solar systems are more positive than those of conventional energy facilities. This is due to the small size, dispersed locations, and gradual implementation of solar heating and cooling of building (SHACOB) systems. (YLB)
- Published
- 1979
86. Haploops similis Stephensen 1925
- Author
-
Kaim-Malka, R. A., Bellan-Santini, D., and Dauvin, J. C.
- Subjects
Arthropoda ,Haploops ,Animalia ,Amphipoda ,Biodiversity ,Ampeliscidae ,Haploops similis ,Malacostraca ,Taxonomy - Abstract
Haploops similis Stephensen 1925 Type species collected by the R. V “ Ingolf”, one specimen, (sex?) length: 4.5 mm, Station 36: 61°50’N – 56°21’W, depth 2702 m, bottom: sediment type unknown. BIOICE material examined. Station 2314: nine specimens, 11September 1992, depth 156 m, 63° 42.16’N – 23°03.50’W; bottom:muddy sand.Station 2328: four specimens, 3 May 1993, depth 429m, 63°20.00’N – 10°57.00’W; bottom: sand. Station 2616: four specimens, 11 July 1994, depth 535 m, 67°11.38’N – 16°50.40’W; bottom: sandy silt. Station 2873: one specimen, 22 August 1996, depth 555 m, 64°37.41’N – 27°14.28’W; bottom: gravely sand. Station 2946: two specimens, 28 August 1996, depth 229 m, 65°47.90’N – 25°38.70’W; bottom: sandy silt. Station 3026: five specimens, 8 July 1997, depth 564 m, 63°53.96’N – 12°44.18’W; sediment type unknown. Station 3099: two specimens, 21August 1999, depth 229 m, 67°11.02’N – 21°45.68’W; bottom: gravely sandy silt. Station 3282: four specimens, 16 September 2001, depth 1808 m, 62°48.00’N – 16°14.80’W; bottom: sandy silt. Station 3531: two specimens, 9 September 2002, depth 1712 m, 62°43.26’N – 14°34.70’W; bottom: sandy silt. Station 3544: 16 specimens, 11September 2002, depth 1632 m, 61°33.005’N – 13°40.14’W; bottom: gravely sand. Station 3598: one specimen, 10 September 2003, depth 768 m, 62°17.37’N – 26°37.58’W; bottom: silty sand. All specimens of these stations are females. Diagnosis. Blind species; body without long dorsal setae on the pereon, pleon and urosome; A1 = 8–9/10 A2, A2 = 2/3 body; coxa 4 heart-shaped, Pereopod 7: basis narrow, anterior distal lobe of the carpus developed. Description. Head: Square shaped, without corneal lenses, anterior margin oblique and straight. Antenna 1 length is 8–9/10 of Antenna 2 length; Antenna 2 length is 2/3 body length. Pereon: without long dorsal setae. Gnathopod 1: coxa 1 roughly oval, distal margin rounded and fringed with long setae; basis long, slightly curved, approximately rectangular with many long setae, as long as ischium + merus + carpus, the merus, carpus and propodus bearing long setae; propodus oval. Gnathopod 2: coxa 2 approximately rectangular, distal margin straight with few setae; basis long, slightly curved, with many long setae, as long as ischium + merus + carpus; the merus, carpus and propodus bearing long setae; propodus oval. Pereopod 3: coxa 3 approximately rectangular, distal margin straight with few setae; basis, merus and carpus with long setae on the posterior margin; dactylus slender, curved and longer than propodus. Pereopod 4: coxa 4 heart-shaped, basis, merus and carpus with long setae on the posterior margin, and tuft of long setae on distal anterior margin of merus and propodus; dactylus slender, curved and shorter than propodus. Pereopod 5: coxa 5 rectangular, basis roughly rectangular with few setae on the anterior margin; carpus rectangular, anterior margin with few setae, posterior margin with rows of little spines, postero-distal lobe with short spines and a long one; propodus rectangular, longer than carpus, with few short setae on anterior margin, and long distal setae; dactylus short and curved. Pereopod 6: basis rounded with few short setae on the anterior margin; carpus rectangular, posterior margin with rows of little spines, postero-distal lobe ornamented with short spines and a very long one; propodus a little longer than carpus, with few short setae on anterior margin, and long distal setae; dactylus short and curved. Pereopod 7: basis narrow, anterior and posterior margin slightly concave, lobe not deflected, rounded with few long setae, not reaching the ischium-merus joint; ischium quadrangular; merus rectangular with an antero-inferior lobe, anterior and posterior margin ornamented with few little spines and long postero-distal setae; carpus oval, with spines on the anterior and posterior margin, anterior distal lobe developed; propodus and dactylus short and narrow. Pleon: without long dorsal setae. Epimeral plate 1: anterior margin oblique and straight, ventral margin and posterior margin straight, corners rounded. Epimeral plate 2: inferior and posterior margins slightly convex, postero-inferior corner rounded. Epimeral plate 3: anterior margin straight, posterior margin oblique and straight, inferior one slightly convex, anterior corner rounded, posterior corner slightly acute. Urosome: carina small. Uropod 1: the rami are long and slender, of unequal length (2/3). Uropod 2: rami short, of equal size, and armed with a row of spines on each ramus. Uropod 3: peduncle short and strong; rami of unequal length, ornamented with numerous setae. Telson: triangular, apically rounded, cleft on 2/3 of the length; two setae at the apex of each lobe. Distribution: North Atlantic Ocean; wide bathymetric range species: this species was collected at 2702m depth (Stephensen,1925), between 100–2900 m (Mills,1971), between 156–1808 m, on sand, sandy silt, silty sand, muddy sand, gravely sand, gravely sandy silt (BIOICE samples), one specimen at 1024 m on bathyal mud in the south of the Bay of Biscay (Dauvin & Bellan-Santini,1996). Taxonomic remarks. H. similis belongs to the sub-group of blind species with a narrow Pereopod 7 basis and without dorsal tuft setae, which includes six other species: H. abyssorum, H. vallifera, H. lodo, H. dauvini, H. bjarnii, and H. faroensis. It differs from these species by having: — Antennae: Antenna 1= 8–9/10 Antenna 2, Antenna 2 = 2/3 body length; the antennae are longer than the body length for H. bjarnii; they are half body length for H. vallifera, H. dauvini, and H. faroensis; for H. lodo, A1= ped A2, A2 shorter than body (in Barnard, 1961). — Coxa 4 heart-shaped (also the case for H. bjarnii and H. vallifera); but square shaped for H. abyssorum, H. lodo, H. dauvini and H. faroensis. — Epimeral plates 3 with posterior margin oblique and straight (also for H. faroensis); slightly convex for H. bjarnii and H. dauvini; rounded for H. vallifera and H. lodo (not indicated by Chevreux 1908 for H. abyssorum). — Uropod 1: the rami are long and slender, of unequal length (2/3); the rami are subequal for H. bjarnii, H. vallifera; H. lodo and H. dauvini; they have the same size for H. abyssorum and H. faroensis., Published as part of Kaim-Malka, R. A., Bellan-Santini, D. & Dauvin, J. C., 2021, Complement to the knowledge of the Haploops species (Crustacea, Gammaridea Ampeliscidae), with the description of two new species from North Atlantic Ocean [Contribution to the knowledge of the Haploops genus. 10.], pp. 151-175 in Zootaxa 5048 (2) on pages 166-168, DOI: 10.11646/zootaxa.5048.2.1, http://zenodo.org/record/5551919, {"references":["Stephensen, K. (1925) Crustacea Malacostraca. VI. (Amphipoda. Il). Danish Ingolf-Expedition, 3, 101 - 178.","Mills, E. L. (1971) Deep-Sea Amphipoda from the Western North Atlantic Ocean, the family Ampeliscidae. Limnology and Oceanography, 16, 357 - 386. https: // doi. org / 10.4319 / lo. 1971.16.2.0357","Dauvin, J. C. & Bellan-Santini, D. (1996) Ampeliscidae (Amphipoda) from the Bay of Biscay. Journal of Crustacean Biology, 16, 149 - 168. https: // doi. org / 10.2307 / 1548938","Barnard, J. L. (1961) Gammaridean Amphipoda from depths of 400 to 6000 meters. Galathea Report, 5, 23 - 128.","Chevreux, E. (1908) Diagnoses d'amphipodes nouveaux provenant des campagnes de l a Princesse Alice dans l'Atlantique nord. Bulletin de l'Institut Oceanographique, Monaco, l 17, 1 - 13."]}
- Published
- 2021
- Full Text
- View/download PDF
87. Haploops vallifera Stephensen 1925
- Author
-
Kaim-Malka, R. A., Bellan-Santini, D., and Dauvin, J. C.
- Subjects
Haploops vallifera ,Arthropoda ,Haploops ,Animalia ,Amphipoda ,Biodiversity ,Ampeliscidae ,Malacostraca ,Taxonomy - Abstract
Haploops vallifera Stephensen 1925. (Figures 9–12) BIOFAR material examined. Station 124, one specimen, 26 July 1987, depth 600 m, 62°16.94’N – 09°38.93’W; sediment type unknown. Station 261, nine specimens, 14 May 1988, depth 1003 m, 61°35.57’N – 09°35.47’W; sediment type unknown. Station 731, 182 specimens, 29 September 1990, depth 1042 m, 60°29.70’N – 07°14.10’W; bottom: sand, gravel, cobbles and stones. Station 738, one specimen, 1 October 1990, depth 749 m, 62°19.30’N – 10°13.30’W; bottom: gravel, cobbles and stones. Male unknown. Diagnosis. Body with few small dorsal setae on the pereon and the pleon. Corneal lenses absent. Segments of dorsal side of mesosome, marked. Urosome segment 1 with a small rounded carena. Epimeral plate 3 rounded. The two pairs of antennae of equal length not longer than half of body. Description. (Fig. 9–12). Adult female (Fig. 9) length 6 mm Biofar 731. Head: nearly square, with a small rostrum, without corneal lenses, blind species, straight lateral lobe. Antenna 1 (Fig. 9, 10 A): nearly equal to half of the body length. Peduncle with article 3 Antenna 2 (Fig. 9, 10 B): Equal to antenna 1 in length. Peduncle segment 5> 4. Flagellum with 12 articles. Mandible (Fig. 10 C): molar strong, palp very long, article 2> article 3, artcles 2, 3 bear long setae, article 3 with a long apical seta. Lower lip bilobate (Fig. 10 F). Maxilla 1 (Fig. 10 E): inner plate conical, outer plate with spine teeth distally, last article of palp ended with some setae and 5 strong teeth. Maxilla 2 (Fig. 10 G): the two plates are subequal in length and apically densely setose. Maxilliped (Fig. 10 D): inner plate sub-rectangular with short setae on the lateral and distal part. Internal margin of the outer plate with numerous long setae and strong teeth. Palp elongate, longer than outer plate, articles 2 and 3 with long setae, article 3 distally enlarged, dactylus elongate slender with 4 setae at the inferior margin. Pereon: small setae on the posterodorsal part of segment 6 and 7 (Fig. 9). Gnathopod 1 (Fig. 11A): longer than gnathopod 2. Coxa 1 as long as basis, distal margin rounded and fringed with long setae. Basis a little longer than carpus+propodus, setose. Merus, carpus and propodus bears long setae, dactylus curved with 5 short setae. Gnathopod 2 (Fig. 11B): Coxa 2 shorter than basis, triangular, distal margin pointed. Basis long with long setae, egal to merus+carpus+propodus. Carpus longer than propodus, roughtly rectangular with long setae mainly on the inferior margin. Propodus roughtly rectangular. Dactylus curved and ornamed with 5 setae. Pereopod 3 (Fig. 11C): Coxa 3 triangular, distal margin pointed. Basis rectangular, basis = ischium + merus + carpus, the margins of the different articles except dactylus, bearing long setae. Dactylus strong, curved, very long, longer than propodus. Pereopod 4 (Fig. 11D): Coxa 4 pointed, shorter and wider than coxa 3, posteriorly excavate, ventral margin straight with one seta on the distal part. Basis rectangular, longer than ischium + merus + carpus. Dactylus curved, as long as propodus. Long setae are present on the margins of all articles except dactylus. Pereopod 5 (Fig. 11E): coxa 5 bilobate, posterior margin rounded. Basis oval anterior margin fringed with short setae. Carpus sub-rectangular with a small postero-distal lobe, posterior and distal margins ornamented with 4 rows of spines. Propodus rectangular, longer than carpus. Dactylus very strong and curved. Pereopod 6 (Fig. 11F): Coxa 6 triangular, distal edge rounded. Basis pyriform with a small indentation at the posterodistal corner. Carpus rectangular with a small distal lobe, posterior and distal margins ornamented with 3 rows of spines. Pereopod 7 (Fig. 12A, B): coxa rectangular, distally rounded. Basis broad, width / length = 1/2, anterior and posterior margins with numerous long setae. Ischium quadrangular with 2 small strong spines on the posterior margin. Merus quadrangular but longer than width. Carpus shorter and narrower of merus with inferior corner elongate. Propodus and dactylus short. Pleon: Segment 1 and 2 with short setae (Fig. 9). Epimeral plate 1: short, ventral margin rounded. Epimeral plate 2 (Fig. 12 F): Rounded distal margin with 2 setae. Epimeral plate 3 (Fig. 12 F): anterior margin straight, anteroventral corner round, vental margin slightly convex, postero-ventral corner rounded, posterior margin convex with 4 setae. Urosome (Fig. 9): segment 1 with a small hump anteriorly at a high rounded dorsal carina. Uropod 1 (Fig. 12C): long, the rami unequal and slightly curved, rami inermous, peduncle longer than rami (peduncle/outer ramus/inner ramous = 40/36/30), ornamented with only one seta at the inner distal corner. Uropod 2 (Fig. 12D): rami subequal, equal to peduncle, one spine on the distal inner corner of the peduncle and 3 on the edge of the inner ramus. Uropod 3 (Fig. 12E): peduncle short and strong, rami foliaceous, longer than peduncle, inner ramus with 2 strong spines, outer ramus with long apical setae and some ones on the margin. Telson (Fig. 12 G): Triangular, rounded, slightly wide than long, cleft on 3/4 of the length, 2 or 3 long setae on each lobe. Known distribution: North Atlantic Ocean; wide bathymetric range species. BIOFAR material, this study, bathymetric range: 600–1042 m; the nature of the bottom is indicated for only two samples: sand, gravel, cobbles and stones. Offshore Iceland, 913–1960 m (Dauvin and Bellan-Santini,1990). Faroe Islands: 600-1098 m (Dauvin 1996), Iceland one station 1392 m (Bellan-Santini and Dauvin, 1997), south and west of Iceland, 13 stations from 285 to 1963 m (Dauvin et al., 2012). Taxonomic remarks. H. vallifera belongs to the sub-group of blind species with a narrow Pereopod 7 basis and without dorsal tuft setae which includes six other species: H. abyssorum, H. similis, H. lodo, H. dauvini, H. bjarnii, and H. faroensis. It differs from these species by having: — Dorsal side of pereon and urosome carinate. — Coxa 1 rectangular with the distal margin rounded. — Coxa 2 triangular, with the distal margin pointed., Published as part of Kaim-Malka, R. A., Bellan-Santini, D. & Dauvin, J. C., 2021, Complement to the knowledge of the Haploops species (Crustacea, Gammaridea Ampeliscidae), with the description of two new species from North Atlantic Ocean [Contribution to the knowledge of the Haploops genus. 10.], pp. 151-175 in Zootaxa 5048 (2) on pages 162-166, DOI: 10.11646/zootaxa.5048.2.1, http://zenodo.org/record/5551919, {"references":["Stephensen, K. (1925) Crustacea Malacostraca. VI. (Amphipoda. Il). Danish Ingolf-Expedition, 3, 101 - 178.","Dauvin, J. C. & Bellan-Santini, D. (1990) An overview of the amphipod genus Haploops (Ampeliscidae). Journal of the Biological Association of the United Kingdom 70, 887 - 903. https: // doi. org / 10.1017 / S 0025315400059129","Bellan-Santini, D. & Dauvin, J. C. (1997) Ampeliscidae (Amphipoda) from Iceland with a description of a new species: Ampelisca islandica (Contribution to the BIOICE programme research). Journal of Natural History, 31, 1157 - 1173. https: // doi. org / 10.1080 / 00222939700770621","Dauvin, J. C., Alizier, S., Weppe, A. & Gudmundsson, G. (2012) Diversity and zoogeography of Icelandic deep-sea Ampeliscidae (Crustacea: amphipoda). Deep Sea Research I, 68, 12 - 23. https: // doi. org / 10.1016 / j. dsr. 2012.04.013"]}
- Published
- 2021
- Full Text
- View/download PDF
88. Complement to the knowledge of the Haploops species (Crustacea, Gammaridea, Ampeliscidae), with the description of two new species from North Atlantic Ocean. [Contribution to the knowledge of the Haploops genus. 10.]
- Author
-
Kaim-Malka, R.A., Bellan-Santini, D., Dauvin, J.C., Institut méditerranéen de biodiversité et d'écologie marine et continentale (IMBE), Avignon Université (AU)-Aix Marseille Université (AMU)-Institut de recherche pour le développement [IRD] : UMR237-Centre National de la Recherche Scientifique (CNRS), Morphodynamique Continentale et Côtière (M2C), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), and Centre National de la Recherche Scientifique (CNRS)-Institut de recherche pour le développement [IRD] : UMR237-Aix Marseille Université (AMU)-Avignon Université (AU)
- Subjects
0106 biological sciences ,Systematic ,North Atlantic Ocean ,Arthropoda ,010607 zoology ,Single pair ,Zoology ,Haploops similis ,010603 evolutionary biology ,01 natural sciences ,Ampeliscidae ,Genus ,Haploops faroensis spec. nov ,Gammaridea ,Haploops spinosa ,Animals ,Animalia ,Amphipoda ,14. Life underwater ,Malacostraca ,Atlantic Ocean ,Ecology, Evolution, Behavior and Systematics ,Taxonomy ,biology ,Fabaceae ,Haploops truncata spec. nov ,Systématique ,Biodiversity ,biology.organism_classification ,Crustacean ,Haploops vallifera ,[SDU]Sciences of the Universe [physics] ,description ,description Résumé Ocean Nord Atlantique ,Animal Science and Zoology - Abstract
(IF 1.02; Q2); International audience; Two new Haploops species are described from the North Atlantic Ocean: a blind species Haploops faroensis spec. nov. and Haploops truncata spec. nov. with a single pair of corneal lenses. In addition, Haploops vallifera Stephensen 1925 and Haploops similis Stephensen 1925, are re-described and the status of Haploops spinosa Shoemaker 1931, is reestablished as a valid species. A table is given of the 75 morphological characters of the studied species.
- Published
- 2021
89. Haploops truncata Kaim-Malka & Bellan-Santini & Dauvin 2021, spec. nov
- Author
-
Kaim-Malka, R. A., Bellan-Santini, D., and Dauvin, J. C.
- Subjects
Arthropoda ,Haploops ,Animalia ,Amphipoda ,Biodiversity ,Ampeliscidae ,Malacostraca ,Haploops truncata ,Taxonomy - Abstract
Haploops truncata spec. nov. (Figures 5–8) Type material. HOLOTYPE. One female without oostegite. Length: 5.57 mm (Fig. 5). BIOICE: Station 3140; one specimen, 25 August 1999, depth: 768 m, 67°51.90’N – 22°14.89’W, bottom: sediment type unknown. Holotype IINH 42245 + slides IINH 42247. The specimen is deposited in the Icelandic Museum of Natural History in Reykjavik (IMNHR). BIOICE material. The specimens are deposited in the Icelandic Museum of Natural History in Reykjavik (IMNHR). Station 2011: one specimen, 20 July 1991, depth: 768 m, 65°41.43’N – 11°16.77’W; sediment type unknown (IINH 42251). Station 2414: three specimens, 20 July 1991, depth 978 m, 65°35.01’N – 10°59.98’W; bottom: brown sandy, silt mixed with foraminifera (IINH 42250). Station 2897: eight specimens, 24 August 1996, depth 672 m, 65°29.44’N – 27°32.55’W; sediment type unknown (IINH 42249). Station 2898: one specimen, 24 August 1996, depth 672 m, 65°29.30’N – 27°32.70’W; sediment type unknown (IINH 42248). Station 3140: one specimen, 25 August 1999, depth 768 m, 67°51.90’N – 22°14.89’W; sediment type unknown (IINH 42245). Station 3501: two specimens, 31 August 2002, depth 829 m, 62°59.84’N – 20°30.25’W; sediment type unknown (IINH 42246). Male unknown. Ethymology. The species name refers to the shape of the head (square) with the lateral lobe truncate. Diagnosis. Pereon, Pleon and Urosome without long dorsal setae, Head square with anterior margin straight (lateral lobe truncate). One pair of superior corneal lenses. Antenna 1 length = 0.8 Antenna 2 length; Antenna 2 as long as body length (0.876). Coxa 4 external side bearing numerous short setae. Description. Holotype. Female without oostegites. Length: 5.57 mm (Fig. 5). Body without long dorsal setae on the pereon, pleon and urosome. Head (Fig. 6A): square with anterior margin straight, one pair of superior corneal lenses. Antenna 1 (Fig. 6B): shorter than antenna 2, peduncle of A1 with article 3 Antenna 2 (Fig. 6C): longer than antenna 1 (A1/A2 = 0.81). Peduncle segment 5 longer than 4 (23/19). Flagellum with 23 articles. Antenna 2 near the body length. The two antennae bearing long numerous setae (Fig. 6B, C). Upper lip and Lower lip bilobate (Fig. 6D, G). Mandible (Fig. 6H): molar strong; palp long, article 2 and 3 of same length; setae are present on the margin of each article, article 3 with very long apical setae. Maxilla 1 (Fig. 6E). the inner plate is conical shaped with two apical setae and some short hairs; outer plate with spine teeth distally; palp ended with strong teeth and spines. Maxilla 2 (Fig. 6F): dense apically setae on the two plates. Maxilliped (Fig. 6J): inner plate sub-rectangular, elongated, with few distal setae; internal margin of the outer plate with long setae and strong teeth; palp elongate, longer than outer plate, article 2 and 3 with long setae, article 3 triangular shaped, dactylus elongate and slender. Pereon: without long dorsal setae (Fig. 5). Gnathopod 1 (Fig. 7A): coxa 1 roughly triangular, distal margin rounded and fringed with long setae; basis long, slightly curved, approximately rectangular with some setae on the two margins, length longer than ischium + merus + carpus, the merus, carpus and propodus bearing long setae; propodus oval; dactylus slender and curved with small setae, dactylus length = 0.51 propodus length. Gnathopod 2 (Fig. 7B): coxa 2 approximately rectangular and short (coxa length / basis length= 65/85), distal margin slightly rounded with few short setae; basis long with some setae, basis longer than ischium + merus +carpus; carpus longer than propodus (carpus length / propodus length = 53/30), approximately rectangular with long setae on the margins; propodus oval, long setae on the margins; dactylus slightly curved with short setae (Fig. 7C), dactylus length = 0.46 (17/37) propodus length. Pereopod 3 (Fig. 7D): coxa 3 triangular, distal margin rounded; basis rectangular, basis> ischium + merus + carpus. The margins of the different articles of pereopod 3, except dactylus, bearing few long setae; dactylus slender, curved and longer than propodus (dactylus length / propodus length = 1.35) (27/20). Pereopod 4 (Fig. 7E): coxa 4 square-shaped, external side bearing numerous short setae; anterior margin straight, length / width = 43/40, antero-ventral corner quadrate but not sharp, ventral margin straight with short setae, posterior concavity = 0.46 (17/37) length of the posterior length of the coxa 4, posterior hook broad, length = 17/42 width of coxa 4, posterior corner blunted; basis length> ischium + merus; the margins of the different articles of pereopod 4, except dactylus, bearing few long setae; dactylus slender, slightly curved and longer than propodus (dactylus length / propodus length = 1.125 (27/24). Pereopod 5 (Fig. 7F): coxa 5 rectangular, basis roughly rectangular with few setae on the anterior margin; carpus rectangular, anterior margin with few setae, posterior margin with two rows of little spines, distal margin with short spines and a long one; propodus rectangular, longer than carpus, with few short setae, and a long distal seta; dactylus short and curved, dactylus length / propodus length = 0.23 (12/51). Pereopod 6 (Fig. 8A): coxa 6 roughly trapezoidal shaped, posterior margin rounded; basis rounded with few short setae and spines on the anterior margin; carpus rectangular, anterior margin with few short setae, posterior margin with two rows of little spines, postero-distal lobe ornamented with short spines and a very long one; propodus a little longer than carpus, with few short setae, and a long distal seta; dactylus short and curved, dactylus length / propodus length = 11/40. Pereopod 7 (Fig. 8B): coxa 7 roughly rectangular; basis narrow (length without lobe / width = 80/35 = 2.28), anterior and posterior margin slightly concave, lobe slightly deflected, rounded with few long setae, reaching the merus; ischium quadrangular; merus rectangular with an antero-inferior lobe ending with a spine, posterior margin ornamented with few little spines; carpus pyriform (width / length = 17/20), with strong spines on the anterior and posterior margin (propodus length / carpus length = 15/20; propodus + dactylus / carpus = 23/20); propodus narrow, width / length = 5/15 (propodus width / carpus width = 5/17), with short apical setae; dactylus rectangular, short and narrow (length / width = 7/1) with two very small apical setae (dactylus length / propodus length = 8/15). Pleon (Fig. 5): the postero-dorsal segments of the pleon without setae. Epimeral plate 1 (Fig. 8C): anterior margin oblique and straight, ventral margin rounded, posterior margin slightly convex. Epimeral plate 2 (Fig. 8C): square shaped, anterior and posterior margin straight, inferior one slightly convex, postero-inferior corner rounded. Epimeral plate 3 (Fig. 8C): square shaped, anterior and posterior margin straight, inferior one slightly convex, corners rounded. Urosome (Fig. 5): the urosome segment 1 has a dorsal carina straight, moderately hight, with the apex rounded. Uropod 1 (Fig. 8D): long, rami slender, curved, and equal length; inner ramus with two little spines; peduncle longer than the ramus, with one spine on the distal margin. length rami / length peduncle = 54–56 / 64. Uropod 2 (Fig. 8E): shorter than Uropod 1; rami triangular and short, inner ramus shorter than the outer one, with a row of spines on each ramus, outer ramus length / peduncle length = 78 /102; peduncle rectangular, robust with a strong spines on the distal margin. Uropod 3 (Fig. 8F): peduncle short and strong (length / width = 58/35); rami of unequal length, roughly rectangular, longer than peduncle (rami length / peduncle length = 90–100/58); inner ramus with three spines and some apical setae, outer ramus with apical long setae and also some long setae on the outer margin. Telson (Fig. 8G): triangular, apically rounded, cleft on 25/35 of the length; one seta present on the apical part of each lobe. Distribution: North Atlantic Ocean; this species was collected between 672 m and 978 m. The nature of the bottom is indicated for only one sample: brown sandy silt mixed with foraminifera. Taxonomic remarks. H. truncata is probably a non mature female, but the original characters in the sub-group with superior corneal lenses justify its description as a new species. H. truncata belongs to the sub-group with the superior pair of corneal lenses clearly visible; the inferior pair is absent; a narrow Pereopod 7 basis, and the absence of dorsal tuft, this sub-group includes six other species: H. tubicola, H. spinosa, H. descansa, H. fundiensis, H. oonah, and H. antennata. H. truncata differs from the other neighbouring species by the following characters: — Head square with anterior margin straight (oblique in H. tubicola; H. spinosa; H. fundiensis; H. antennata). — Antennae subequal, Antenna 2 near the body length; in H. tubicola, the antennae are subequal and reach 2/3 of the body length; they reach 1/3 of the body length for H. fundiensis; in H. spinosa the Antenna 2 length is include between 1/3 and 1/2 of body length. For the two other species, H. descansa and H. oonah, the Antenna 1 is half the length of Antenna 2; whereas in H. antennata, the Antenna 1 is longer than Antenna 2. — Coxa 4 square-shaped, external side bearing numerous short setae. — Epimeral plate 3 square shaped; the posterior margin is oblique or slightly curved in the other species (except for H. descansa). — Uropod 1 long, with rami slender, curved, and of equal length; they are of unequal length for H. tubicola, H. descansa, H. fundiensis, H. oonah and H. antennata (except H. spinosa with rami of equal length, and especially as Uropod 2 rami are strongly armed). In the introduction we indicate that it is necessary to supplement the description of two species described by Stephensen in 1925: Haploops vallifera and Haploops similis. This is the object of the following section.
- Published
- 2021
- Full Text
- View/download PDF
90. Haploops Liljeborg 1856
- Author
-
Kaim-Malka, R. A., Bellan-Santini, D., and Dauvin, J. C.
- Subjects
Arthropoda ,Haploops ,Animalia ,Amphipoda ,Biodiversity ,Ampeliscidae ,Malacostraca ,Taxonomy - Abstract
Key to species of Haploops 1 Corneal lenses present................................................................................. 2 - Corneal lenses absent................................................................................. 17 2 Two pairs of corneal lenses............................................................................. 3 - Only one pair of corneal lenses.......................................................................... 8 3 Pereopod 7 basis broad................................................................................. 4 - Pereopod 7 basis narrow................................................................................ 5 4 P7 carpus with anterior distal lobe; coxa1 inferior margin straight.......................... Haploops laevis Hoek, 1882 - P7 carpus without anterior distal lobe; coxa1 inferior margin rounded............................................................................................ Haploops quebecoisis Bellan-Santini Kaïm-Malka & Dauvin, 2018 5 Inferior lenses in the middle of the lobe head................................... Haploops sibirica Gurjanova, 1929 - Inferior lenses near or on the margin head.................................................................. 6 6 Inferior lenses near the margin head.......................................... Haploops dellavallei Chevreux, 1900 - Inferior lenses on the margin head........................................................................ 7 7 Inferior lenses on the margin, antennae = body length............................. Haploops nirae Kaïm-Malka, 1976 - Inferior lenses on the internal side of the margin, antennae = 1/2 body length........... Haploops tenuis Kanneworff, 1966 8 Only inferior lenses present (superior absent)............................................................... 9 - Only superior lenses present (inferior absent).............................................................. 10 9 Long setae on Md, back, telson, A1 Haploops longiseta Kaïm-Malka, 2010 - Few long dorsal setae, A1> A 2.............................................. Haploops proxima Chevreux, 1919 10 Pereopod 7 basis broad, A 2> body................................ Haploops gascogni Dauvin & Bellan-Santini, 1996 - Pereopod 7 basis narrow............................................................................... 11 11 Head truncated straight................................................................................ 12 - Head transversely truncated............................................................................ 15 12 A1> A 2.............................................................. Haploops antennata Kaïm-Malka, 2012 - A1 Haploops descansa Barnard, 1961 - A1 length> A2 peduncle.............................................................................. 14 14 A1 length a little more A 2 peduncle; coxa 1 oval; U1 rami unequal length.......... Haploops oonah Lowry & Poore, 1985 - A1= 2/3 A2, A2 = body; coxa 1 triangular; outer side coxa 4 setose; U1 rami equal length.... Haploops truncata spec. nov. 15 A 2 = 1/2 body; corneal lenses great size......................................... Haploops tubicola Liljborg, 1856 - A 2 = 1/3 body; corneal lenses small size.................................................................. 16 16. U1–2 strongly armed....................................................... Haploops spinosa Shoemaker 1931 - U1–2 weakly armed............................................. Haploops fundiensis Wildish & Dickinson, 1982 17 Pereopod 7 basis narrow............................................................................... 18 - Pereopod 7 basis broad................................................................................ 24 18 P7 basis, merus and carpus, rectangular and slender (male)....................... Haploops abyssorum Chevreux, 1908 - P7 basis, merus and carpus, not rectangular and slender...................................................... 19 19 Coxa 4 heart-shaped.................................................................................. 20 - Coxa 4 not heart-shaped............................................................................... 22 20 Dorsal side of the body carinate, coxa 2 acute................................... Haploops vallifera Stephensen,1925 - Dorsal side of the body not carinate...................................................................... 21 21 A1= 8–9/10 A 2, A2= 2/3 body............................................... Haploops similis Stephensen, 1925 - Antennae longer than the body length..................... Haploops bjarnii Bellan-Santini Kaïm-Malka & Dauvin, 2018 22 A1= A 2 peduncle, coxa1 oval.................................................... Haploops lodo Barnard, 1961 - Antennae Haploops dauvini Peart, 2018 - A1=A2=1/2 body length......................................................... Haploops faroensis spec. nov. 24 Long dorsal tuft of setae absent......................................................................... 25 - Long dorsal tuft of setae present........................................................................ 26 25 P7 basis lobe exceeding ischium distal edge; A1Haploops antarctica Bellan-Santini & Dauvin, 2008 - P7 basis lobe not exceeding ischium distal edge; A1=A2; coxa 4 heart-shaped............ Haploops kaimmalkai Peart, 2018 26 Long dorsal tuft of setae (pereon 5–7 & pleon), P7 basis lobe triangular................... Haploops setosa Boeck, 1870 - Long dorsal tuft of setae (pereon 5–7 & pleon), P7 basis lobe rounded............................................27 27 Urosome 1 high upturned carina.............................................. Haploops carinata Liljeborg, 1856 - Urosome 1 carina straight.............................................................................. 28 28 Antenna length> body length, antennae very strong...... Haploops islandica Kaïm-Malka,Bellan-Santini & Dauvin, 2016 - Antenna length =1/2 body length............................................... Haploops robusta G.O. Sars, 1891, Published as part of Kaim-Malka, R. A., Bellan-Santini, D. & Dauvin, J. C., 2021, Complement to the knowledge of the Haploops species (Crustacea, Gammaridea Ampeliscidae), with the description of two new species from North Atlantic Ocean [Contribution to the knowledge of the Haploops genus. 10.], pp. 151-175 in Zootaxa 5048 (2) on page 173, DOI: 10.11646/zootaxa.5048.2.1, http://zenodo.org/record/5551919, {"references":["Hoek, P. P. C. (1882) Die Crustaceen, gesammelt waehrend der Fahrten des \" Willem Barents \" in den Jahren 1878 und 1879, Niederlandisches Archiv fur Zoologie, Supplement band I, 7, 61.","Gurjanova, E. F. (1929) Neue Forrnen arktischer Isopoden und Amphipoden. Zoologischer Anzeiger, 81, 309 - 317.","Chevreux, E. (1900) Amphipodes provenant des campagnes de l'Hirondelle (1885 - 1888). Resultats des Campagnes Scientifiques Accomplies par le Prince Albert I. Monaco. 16, 195 pp.","Kaim-Malka, R. A. (1976) Revision des Haploops (Crustacea, Amphipoda) de Mediterranee. Bolletino del Museo Civico di Storia Naturale, Verona, 3, 269 - 308.","Kanneworff, E. (1966) On some amphipod species of the genus Haploops, with special reference to H. tubicola Liljeborg and H. tenuis sp. nov. from the Oresund. Ophelia, 3, 183 - 207.","Kaim-Malka, R. A. (2010) Haploops longiseta, a new species from the Atlantic Ocean (Crustacea, Gammaridea, Ampeliscidae). [Contribution to the knowledge of the Haploops genus. 6]. Zootaxa, 2356 (1), 57 - 68. https: // doi. org / 10.11646 / zootaxa. 2356.1.3","Chevreux, E. (1919) Note preliminaire sur les Amphipodes recueillis par les expeditions du \" Travailleur \" et du \" Talisman \" (1880 - 1883). Bulletin du Museum d'Histoire Naturelle, 25, 574 - 580. https: // doi. org / 10.5962 / bhl. part. 7932","Dauvin, J. C. & Bellan-Santini, D. (1996) Ampeliscidae (Amphipoda) from the Bay of Biscay. Journal of Crustacean Biology, 16, 149 - 168. https: // doi. org / 10.2307 / 1548938","Kaim-Malka, R. A. (2012) Haploops antennata, a new species from the North Atlantic Ocean (Crustacea: Gammaridea: Ampeliscidae). [Contribution to the knowledge of the Haploops genus. 7]. Zootaxa, 3320 (1), 36 - 46. https: // doi. org / 10.11646 / zootaxa. 3320.1.2","Barnard, J. L. (1961) Gammaridean Amphipoda from depths of 400 to 6000 meters. Galathea Report, 5, 23 - 128.","Lowry, J. K. & Poore, G. C. B. (1985) The ampeliscid amphipods of south-eastern Australia (Crustacea). Records of the Australian Museum, 36, 259 - 298. https: // doi. org / 10.3853 / j. 0067 - 1975.36.1985.348","Shoemaker, C. R. (1931) The Stegocephalid and Ampeliscid Amphipod Crustaceans of Newfoundland, Nova Scotia, and New Brunswick in t he United States National Museum. Proceedings of the United States National Museum, 79 (2888), 1 - 18, 6 figs. https: // doi. org / 10.5479 / si. 00963801.79 - 2888.1","Wildish, D. J. & Dickinson, J. J. (1982) A new species of Haploops (Amphipoda, Ampeliscidae) from the Bay of Fundy. Canadian Journal of Zoology, 60, 962 - 967. https: // doi. org / 10.1139 / z 82 - 133","Chevreux, E. (1908) Diagnoses d'amphipodes nouveaux provenant des campagnes de l a Princesse Alice dans l'Atlantique nord. Bulletin de l'Institut Oceanographique, Monaco, l 17, 1 - 13.","Stephensen, K. (1925) Crustacea Malacostraca. VI. (Amphipoda. Il). Danish Ingolf-Expedition, 3, 101 - 178.","Peart, R. A. (2018) Ampeliscidae (Crustacea, Amphipoda) from the IceAGE expeditions. Zookeys, 731, 145 - 173, 2 tabs. https: // doi. org / 10.3897 / zookeys. 731.19948","Boeck, A. (1870) Crustacea Amphipoda Borealia et Arctica. Forhandlinger i Videnskabs-Selskabet i Christiania 1870, pp. 83 - 280. https: // doi. org / 10.5962 / bhl. title. 2056","Liljeborg, W. (1856) Om Hafs-Crustaceer vid Kullaberg i Skane. Ofversigt af Kongliga Vetenskaps - Akademien Forhandlingar, Stockholm, 12, 117 - 138.","Kaim-Malka, R., Bellan-Santini, D. & Dauvin, J. C. (2016) On some Haploops species collected in the North Atlantic Ocean with the description of Haploops islandica n. sp. (Crustacea: Gammaridea: Ampeliscidae) [Contribution to the knowledge of the Haploops genus. 8]. Zootaxa, 4179 (1), 42 - 76. https: // doi. org / 10.11646 / zootaxa. 4179.1.2","Sars, G. O. (1891) Amphipoda. An Account of the Crustacea of Norway with short descriptions and figures of all the species, 1, 191 - 196, pls. 67 - 68."]}
- Published
- 2021
- Full Text
- View/download PDF
91. Haploops faroensis Kaim-Malka & Bellan-Santini & Dauvin 2021, spec. nov
- Author
-
Kaim-Malka, R. A., Bellan-Santini, D., and Dauvin, J. C.
- Subjects
Arthropoda ,Haploops faroensis ,Haploops ,Animalia ,Amphipoda ,Biodiversity ,Ampeliscidae ,Malacostraca ,Taxonomy - Abstract
Haploops faroensis spec. nov. (Figures 1–4) Type material. HOLOTYPE. One adult female with oostegites not completely developed. Length: 9.18 mm (Fig.1). BIOFAR: Station 299, one specimen, 17 July 1988, depth: 923 m, 60° 10.80’N – 08° 17.30’ W; bottom: clay and silt, sand, gravel. Holotype + slides (NHMD – 873179). The specimen is deposited in the Natural History Museum of Denmark (Danish Statens Naturhistoriske Museum). BIOFAR material. The specimens are deposited in the Natural History Museum of Denmark. Station 269, five specimens, 15 May 1988, depth: 510 m, 62° 49.84’N – 08° 15.55’ W; bottom: mud, sand, cobbles and stones (NHMD-873180). Station 271, four specimens, 16 May 1988, depth: 559 m, 62° 52.30’N – 08° 09.24’W; bottom: soft bottom, foraminifers (NHMD-873181). Station 299, one specimen, 17 July 1988, depth: 923 m, 60° 10.80’N – 08° 17.30’W; bottom: clay and silt, sand, gravel (NHMD-873179). BIOICE material. The specimens are deposited in the Icelandic Museum of Natural History in Reykjavik (IMNHR). Station 2673, nine specimens, 15 July 1994, depth: 227– 222 m, 66° 50.20’N – 16°15.74’W; bottom: sponge spicules. (IINH 42254). Station 3522, five specimens, 7 September 2002, depth: 1940 m, 62°31.14’N – 17° 09.87’W, bottom: sediment type unknown (IINH 42253). Station 3544, one specimen, 11 September 2002, depth: 1635– 1632 m, 61°33.00’N – 13°40.14’W, bottom: gravely sand. (IINH 42252). Male unknown. Etymology. The species name refers to the area of the Faroe Islands where the species was collected. Diagnosis. Blind species. Pereon, Pleon and Urosome without long dorsal setae. Antenna 1 and Antenna 2 have the same length. Antennae half length of the body. Pereopod 7 basis narrow. Description. Holotype. Adult female, 9.18 mm (Fig.1). Body without long dorsal setae on the pereon, pleon and urosome. Head (Fig. 2A): rectangular, with a short rostrum pointed, without corneal lenses, blind species. Anterior margin oblique and straight. Antenna 1 (Fig. 2B): as long as antenna 2, half length of the body, peduncle of A1 with article 3 Antenna 2 (Fig. 2C): as long as antenna 1. Peduncle segment 5 longer than 4 (24/20). Flagellum with 17 articles. The two antennae bearing long setae. Upper lip, and Lower lip bilobate. Mandible (Fig. 2D): molar strong; palp long, article 3 longer than article 2 (3/2 = 40/35), setae are present on the margin of each article, article 3 with 3 long apical setae. Maxilla 1 (Fig. 2G): the inner plate is conical shaped with one long apical seta; outer plate with spine teeth distally; palp ended with strong teeth and spines. Maxilla 2 (Fig. 2H): dense apically setae on the two plates. Maxilliped (Fig. 2E): inner plate sub-rectangular, elongated; internal margin of the outer plate with long setae and strong teeth; palp elongate, longer than outer plate, articles 2 and 3 with long setae, article 3 oval shape, dactylus elongate and slender (Fig. 2F). Pereon: without long dorsal setae (Fig. 1). Gnathopod 1 (Fig. 3A): coxa 1 roughly triangular, distal margin rounded and fringed with long setae; basis as long as ischium + merus + carpus, more broad on the distal part than proximal one, with some setae on the two margins, the merus, carpus and propodus bearing long setae; propodus oval; dactylus strongly curved, (Fig. 3B), dactylus length = 0.6 propodus length. Gnathopod 2 (Fig. 3C): coxa 2 approximately rectangular and short (coxa length / basis length = 30/33), distal margin straight with few short setae; basis long, rectangular, with some long setae, basis = ischium + merus + carpus; carpus longer than propodus (carpus length / propodus length = 26/15), approximately rectangular with long setae on the margins; propodus oval, long setae on the margins; dactylus slightly curved with short setae (Fig. 3D), dactylus length = 1/3 propodus length. Pereopod 3 (Fig. 3E): coxa 3 rectangular, distal margin rounded; basis rectangular, basis longer than ischium + merus + carpus. The margins of the different articles of pereopod 3, except ischium and dactylus, bearing few long setae; dactylus slender, curved and as long as propodus (dactylus length / propodus length = 1). Pereopod 4 (Fig. 3F): coxa 4 square-shaped, anterior margin straight, length / width = 40/34, antero-ventral corner rounded, ventral margin slightly curved with short setae, posterior concavity 1/2 length of the posterior length of the coxa 4, posterior hook broad, length = 12/34 width of coxa 4, posterior corner rounded; basis longer than ischium + merus + carpus; the margins of the different articles of pereopod 4, except dactylus, bearing many long setae; dactylus slender, curved and longer than propodus (dactylus length / propodus length = 21/17). Pereopod 5 (Fig. 3G): coxa 5 roughly rectangular, bi-lobated; basis oval with few short setae on the anterior margin; carpus rectangular, anterior margin with two short setae, posterior margin with two rows of little spines, postero-distal lobe ornamented with short spines and a long seta; propodus rectangular a little longer than carpus, with few short setae on the anterior margin, and long distal setae; dactylus slender and curved, dactylus length / propodus length = 12/40 (0.3). Pereopod 6 (Fig. 4A): coxa 6 roughly rectangular, posterior margin rounded; basis rounded with few short setae on the anterior margin; carpus rectangular, anterior margin with few short spines, posterior margin with two rows of little spines, postero-distal lobe ornamented with short spines and a long one; propodus rectangular a little shorter than carpus, with few short setae, and a long distal seta; dactylus slender and curved, dactylus length / propodus length = 8/21. Pereopod 7 (Fig. 4B): coxa 7 roughly rectangular, posterior margin rounded; basis narrow (length without lobe / width = 40/20), anterior margin slightly concave, numerous long setae on posterior margin, lobe slightly deflected, rounded with few long setae, reaching the merus; ischium quadrangular; merus rectangular with spines on the margins and long setae on the posterior one; carpus rectangular (width / length = 8/12), with small spines on the anterior and posterior margins and one spine on the posterodistal corners (propodus length / carpus length = 4/12; propodus + dactylus / carpus = 8/12); propodus narrow, width / length = 2/4 (propodus width / carpus width = 2/8), with a short apical seta; dactylus rectangular, short and narrow (length / width = 3/1) with two very small apical setae (dactylus length / propodus length = 3/4). Pleon (Fig. 1): the postero-dorsal segments of the pleon without setae. Epimeral plate 1 (Fig. 4G): anterior margin oblique and straight, ventral margin and posterior one straight, inferior corners rounded. Epimeral plate 2 (Fig. 4G): rounded. Epimeral plate 3 (Fig. 4G): anterior margin straight, antero-ventral corner rounded, ventral margin straight, postero-ventral corner acute, posterior margin oblique and straight. Urosome (Fig. 4H): the urosome segment 1 has a dorsal carina straight, moderately hight, with the apex rounded. Uropod 1 (Fig. 4C): long, rami slender, curved, and equal length; inner ramus with two little spines; peduncle longer than the rami, with 1 spine on the distal margin. length rami / length peduncle = 38 / 52. Uropod 2 (Fig. 4D): shorter than uropod 1; rami triangular, inner ramus longer than the outer one, with a row of five little spines on inner ramus and only two spines on outer, outer ramus length / peduncle length = 36 /41; peduncle rectangular, robust with spines on the inner margin. Uropod 3 (Fig. 4E): peduncle short and strong (length / width = 25/15); rami of equal length, roughly rectangular, longer than peduncle (rami length / peduncle length = 35/25); inner ramus with three spines and some apical setae, outer ramus with an apical tuft of long setae and also some long setae on the outer margin. Telson (Fig. 4F): rectangular, apically rounded, cleft on 33/45 of the length; one spine and one seta are present on the apical part of each lobe. Distribution: North Atlantic Ocean; wide bathymetric range species: 222–1940 m, present mainly in soft sediments: mud, sand, gravely sand, clay and silt, gravel, cobbles and stones, foraminifers, sponge spicules. Taxonomic remarks. H. faroensis spec. nov. belongs to the sub-group of blind species with a narrow pereopod 7 basis and without dorsal tuft seta e. This sub-group includes six other species: H. abyssorum, H. similis, H. vallifera, H. lodo, H. dauvini and H. bjarnii. It differs from these species in having: — Antennae of the same length and as long as half body length; Antenna 2 = 2/3 body length for H. similis; the antennae are longer than the body length for H. bjarnii; for H. lodo, A1= ped A2, A2 shorter than body (in Barnard 1961) (they are half body length for H. vallifera, H. dauvini and H. faroensis), — Coxa 4 square-shaped, heart-shaped for H. bjarnii, H. vallifera, H. similis, but also square- shaped for H. abyssorum, H. lodo and H. dauvini. — Epimeral plate 3 with posterior margin oblique and straight (also for H. similis); slightly convex for H. bjarnii, H. dauvini, rounded for H. vallifera, H. lodo (not indicated by Chevreux 1908 for H. abyssorum). — Uropod 1: rami of same size (also for H. abyssorum), they are of unequal length (2/3 for H. similis), the rami are subequal for H. bjarnii, H. vallifera, H. lodo and H. dauvini.
- Published
- 2021
- Full Text
- View/download PDF
92. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience
- Author
-
Pizzuti, L, Giordano, A, Michelotti, A, Mazzotta, M, Natoli, C, Gamucci, T, De Angelis, C, Landucci, E, Diodati, L, Iezzi, L, Mentuccia, L, Fabbri, A, Barba, M, Sanguineti, G, Marchetti, P, Tomao, S, Mariani, L, Paris, I, Lorusso, V, Vallarelli, S, Cassano, A, Airoldi, F, Orlandi, A, Moscetti, L, Sergi, D, Sarobba, M, Tonini, G, Santini, D, Sini, V, Veltri, E, Vaccaro, A, Ferrari, L, De Tursi, M, Tinari, N, Grassadonia, A, Greco, F, Botticelli, A, La Verde, N, Zamagni, C, Rubino, D, Cortesi, E, Magri, V, Pomati, G, Scagnoli, S, Capomolla, E, Kayal, R, Scinto, A, Corsi, D, Cazzaniga, M, Laudadio, L, Forciniti, S, Mancini, M, Carbognin, L, Seminara, P, Barni, S, Samaritani, R, Roselli, M, Portarena, I, Russo, A, Ficorella, C, Cannita, K, Carpano, S, Pistelli, M, Berardi, R, De Maria, R, Sperduti, I, Ciliberto, G, Vici, P, Pizzuti L., Giordano A., Michelotti A., Mazzotta M., Natoli C., Gamucci T., De Angelis C., Landucci E., Diodati L., Iezzi L., Mentuccia L., Fabbri A., Barba M., Sanguineti G., Marchetti P., Tomao S., Mariani L., Paris I., Lorusso V., Vallarelli S., Cassano A., Airoldi F., Orlandi A., Moscetti L., Sergi D., Sarobba M. G., Tonini G., Santini D., Sini V., Veltri E., Vaccaro A., Ferrari L., De Tursi M., Tinari N., Grassadonia A., Greco F., Botticelli A., La Verde N., Zamagni C., Rubino D., Cortesi E., Magri V., Pomati G., Scagnoli S., Capomolla E., Kayal R., Scinto A. F., Corsi D., Cazzaniga M., Laudadio L., Forciniti S., Mancini M., Carbognin L., Seminara P., Barni S., Samaritani R., Roselli M., Portarena I., Russo A., Ficorella C., Cannita K., Carpano S., Pistelli M., Berardi R., De Maria R., Sperduti I., Ciliberto G., Vici P., Pizzuti, L, Giordano, A, Michelotti, A, Mazzotta, M, Natoli, C, Gamucci, T, De Angelis, C, Landucci, E, Diodati, L, Iezzi, L, Mentuccia, L, Fabbri, A, Barba, M, Sanguineti, G, Marchetti, P, Tomao, S, Mariani, L, Paris, I, Lorusso, V, Vallarelli, S, Cassano, A, Airoldi, F, Orlandi, A, Moscetti, L, Sergi, D, Sarobba, M, Tonini, G, Santini, D, Sini, V, Veltri, E, Vaccaro, A, Ferrari, L, De Tursi, M, Tinari, N, Grassadonia, A, Greco, F, Botticelli, A, La Verde, N, Zamagni, C, Rubino, D, Cortesi, E, Magri, V, Pomati, G, Scagnoli, S, Capomolla, E, Kayal, R, Scinto, A, Corsi, D, Cazzaniga, M, Laudadio, L, Forciniti, S, Mancini, M, Carbognin, L, Seminara, P, Barni, S, Samaritani, R, Roselli, M, Portarena, I, Russo, A, Ficorella, C, Cannita, K, Carpano, S, Pistelli, M, Berardi, R, De Maria, R, Sperduti, I, Ciliberto, G, Vici, P, Pizzuti L., Giordano A., Michelotti A., Mazzotta M., Natoli C., Gamucci T., De Angelis C., Landucci E., Diodati L., Iezzi L., Mentuccia L., Fabbri A., Barba M., Sanguineti G., Marchetti P., Tomao S., Mariani L., Paris I., Lorusso V., Vallarelli S., Cassano A., Airoldi F., Orlandi A., Moscetti L., Sergi D., Sarobba M. G., Tonini G., Santini D., Sini V., Veltri E., Vaccaro A., Ferrari L., De Tursi M., Tinari N., Grassadonia A., Greco F., Botticelli A., La Verde N., Zamagni C., Rubino D., Cortesi E., Magri V., Pomati G., Scagnoli S., Capomolla E., Kayal R., Scinto A. F., Corsi D., Cazzaniga M., Laudadio L., Forciniti S., Mancini M., Carbognin L., Seminara P., Barni S., Samaritani R., Roselli M., Portarena I., Russo A., Ficorella C., Cannita K., Carpano S., Pistelli M., Berardi R., De Maria R., Sperduti I., Ciliberto G., and Vici P.
- Abstract
Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.
- Published
- 2019
93. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
- Author
-
Cazzaniga, M, Pinotti, G, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Fiorentini, G, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Melegari, E, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Clivio, L, Torri, V, Cicchiello, F, Riva, F, Vallini, I, Mazza, M, Bonfadini, C, Bordin, E, Canicatti, M, Cappuccio, F, Collova, E, De Angelis, C, Desorte, R, Donati, S, Drudi, G, Galanti, D, Mocerino, C, Orlando, L, Pellegrino, B, Pizzuti, L, Ridolfi, C, Rocca, A, Sarti, D, Spagnoletti, I, Tinari, N, Vandone, A, Vizzini, L, Cazzaniga M. E., Pinotti G., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Fiorentini G., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Marchetti P., Melegari E., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Saracchini S., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Clivio L., Torri V., Cicchiello F., Riva F., Vallini I., Mazza M., Bonfadini C., Bordin E., Canicatti M., Cappuccio F., Collova E., De Angelis C., Desorte R., Donati S., Drudi G., Galanti D., Mocerino C., Orlando L., Pellegrino B., Pizzuti L., Ridolfi C., Rocca A., Sarti D., Spagnoletti I., Tinari N., Vandone A., Vizzini L., Cazzaniga, M, Pinotti, G, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Fiorentini, G, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Melegari, E, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Clivio, L, Torri, V, Cicchiello, F, Riva, F, Vallini, I, Mazza, M, Bonfadini, C, Bordin, E, Canicatti, M, Cappuccio, F, Collova, E, De Angelis, C, Desorte, R, Donati, S, Drudi, G, Galanti, D, Mocerino, C, Orlando, L, Pellegrino, B, Pizzuti, L, Ridolfi, C, Rocca, A, Sarti, D, Spagnoletti, I, Tinari, N, Vandone, A, Vizzini, L, Cazzaniga M. E., Pinotti G., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Fiorentini G., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Marchetti P., Melegari E., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Saracchini S., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Clivio L., Torri V., Cicchiello F., Riva F., Vallini I., Mazza M., Bonfadini C., Bordin E., Canicatti M., Cappuccio F., Collova E., De Angelis C., Desorte R., Donati S., Drudi G., Galanti D., Mocerino C., Orlando L., Pellegrino B., Pizzuti L., Ridolfi C., Rocca A., Sarti D., Spagnoletti I., Tinari N., Vandone A., and Vizzini L.
- Abstract
Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3–10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8–11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3–15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.
- Published
- 2019
94. Novel drugs, familiar interactions: ciprofloxacin may increase exposure to the RET inhibitor pralsetinib
- Author
-
Citarella, F., Russano, M., Galletti, A., Vincenzi, B., Tonini, G., and Santini, D.
- Published
- 2021
- Full Text
- View/download PDF
95. Comparing Estimates of Fuel Economy Improvement Via Fuel-Cell Powertrains
- Author
-
Santini, D. J., Vyas, A. D., Kumar, R., and Anderson, J. L.
- Published
- 2002
96. 966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy
- Author
-
Cortellini, A., primary, Mallardo, D., additional, Cleary, S., additional, Bersanelli, M., additional, Santini, D., additional, Tucci, M.G., additional, Russo, A., additional, Rastelli, F., additional, Filetti, M., additional, Gelibter, A.J., additional, Marconcini, R., additional, Chiari, R., additional, Grossi, F., additional, De Tursi, M., additional, Queirolo, P., additional, Zoratto, F., additional, Tanda, E.T., additional, Porzio, G., additional, Ascierto, P.A., additional, and Pinato, D.J., additional
- Published
- 2021
- Full Text
- View/download PDF
97. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy
- Author
-
Treré, D., Brighenti, E., Donati, G., Ceccarelli, C., Santini, D., Taffurelli, M., Montanaro, L., and Derenzini, M.
- Published
- 2009
- Full Text
- View/download PDF
98. Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients
- Author
-
Vincenzi, B., Santini, D., Perrone, G., Russo, A., Adamo, V., Rizzo, S., Castri, F., Antinori, A., Alloni, R., Crucitti, P.F., Morini, S., Rabitti, C., Vecchio, F.M., Magistrelli, P., Coppola, R., and Tonini, G.
- Published
- 2009
- Full Text
- View/download PDF
99. P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer
- Author
-
Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, S., Melisi, D., Antonuzzo, L., Pellegrino, A., and Aprile, G.
- Published
- 2016
- Full Text
- View/download PDF
100. Second-line chemotherapy in advanced biliary cancer: the present now will later be past
- Author
-
Vivaldi, C., Fornaro, L., Cereda, S., Aprile, G., Santini, D., Silvestris, N., Lonardi, S., Leone, F., Milella, M., Brandi, G., and Vasile, E.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.